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Post-translational modifications (PTMs) are covalent processing events that change the 
properties of a protein subsequently to its synthesis. Far from being mere “decorations”, 
PTMs of a protein can determine its activity state, localization, turnover, and interactions 
with other proteins [1]. 
Accordingly, multiple diseases could be caused or manifested by PTMs. For instance, an 
investigation carried out in our laboratory through the characterization of tissue-specific 
PTMs demonstrated that mitochondrial hereroplasmy induced oxidative modifications in 
the heart that mainly affects the proteins of the oxidative phosphorylation system 
(OXPHOS) [2]. Some studies relate oxidative post-translational modifications [3,4], 
citrullination, carbamylation [5], glycosylation [6,7], homocysteinylation [8], low density 
lipopoprotein (LDL) oxidation [9], matrix gamma-carboxyglutamic acid protein post-
translational modification and cell specific histone modification with atherosclerosis 
disease [10,11]. These findings highlight the clinical importance of PTMs in the expansion 
of this significant disease, and their potential use as biomarkers. 
Mass spectrometry (MS) is the most powerful tool to characterize PTMs. It is estimated 
that during traditional MS/MS sequence database searches a huge amount [12], about 60%, 
of the spectra cannot be assigned since they stem from peptides that contain unknown 
sequence variations or post-translational or chemical modifications. An exact match 
between observed and predicted fragments is required and increasingly narrow (ppm) 
precursor and fragment tolerances are used due to the of high-resolution instruments. 
However, the classical approach has several limitations since the modification to be 
searched must be selected in advance and that only up to eight PTMs are searched at the 
same time, since otherwise would compromise search time and identification reliability 
[13,14]. With this regard, the open search strategy (“Open Search”) has revolutionized the 
field, based on wide mass windows for the precursors and narrow for the fragments, 
allowing the detection of any kind of modification detectable by MS, successfully 
identifying modified peptides at an unprecedented scale by implementing tolerances in the 
order of hundreds of Daltons for the precursor mass [15]. Nonetheless, originally, the 
approach was only capable of identifying half of the potentially detectable modifications 
and without locating the position of the modified residue. In addition, there was a lack of 
tools for the quantitative analysis of PTM. 
In the recent years, the Open Search-based tools for unbiased PTM identification have 
experienced a quick development in the proteomics community [1-13]. The Comet-PTM 
pipeline developed in our laboratory [2], constitutes a breakthrough in Open Search PTM 
analysis, since it calculates the mass difference between the experimental and all the 
possible theoretical precursors present in the database, adding this variation in mass 
(Δmass) to all the fragments and calculates a score for all the resulting sequence 
candidates, keeping the candidate with the best score, which is also the modified site. 
Thanks to this feature, CometPTM outperforms the traditional OpenSearch strategy, 
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identifying all detectable modifications and their positions within the peptide sequence. 
Moreover, the pipeline includes tools for the simultaneous quantitative analysis of 
modified peptides, proteins and functional categories on the bases of a robust statistical 
model [16]. 
 
Although the hypothesis-free PTM analyses constitute a radical improvement in the 
comprehensive study of PTMs by MS, they still face many challenges. For instance, the 
already high complexity of the Δmass histograms is increased due to unaccounted semi-
tryptic or non-tryptic cuts, monoisotopic peak assignment errors, adduct formation and 
ammonia or water losses, among other factors. It is thus fundamental to be able to take into 
account all these peptide forms to achieve unbiased quantitative results. Additionally, in 
many cases the quality of the spectrum is not adequate enough to accurately locate the 
modified peptide position. In such cases the modification is found spread along the whole 
peptide sequence, increasing the variability among experiments and lowering the statistical 
power to detect abundance changes. Finally, the PTM analysis results in very long list of 
Δmasses and there are no tools to classify them into ontologies, hindering a system-wide 
quantitative study that would most definitely help to reveal the meaningful biological 
information.  
 
Atherosclerosis and subsequent cardiovascular diseases are the leading causes of death 
worldwide [17]. It is a lipid-driven, chronic inflammatory disease that develops plaque 
formation at specific sites of the arterial tree leading to hardening and narrowing of the 
arterial lumen [18]. Diabetes, current smoking, hypertension, hyperlipidemia and male 
gender are common risk factors of this disease related with vascular inflammation [19]. 
PTMs also have been implicated in atherosclerosis [2-11]. With this regard, using the Low 
Densitty Lypoprotein receptor deficient (LDLR KO) mouse model, it was demonstrated 
that atherosclerosis can be attenuated by the pharmacological inhibition of tyrosine 
phosphatase 1B [20], and the genetic deficiency of Tyrosyl protein Sulfotransferase [21], 
although the molecular mechanisms involved are still unknown. PTMs also play a role in 
vascular calcification [10], a process that occurs in association with atherosclerotic lesions 
development [22]. Thus matrix gamma-carboxyglutamic acid protein (MGP) expressed by 
vascular smooth muscle cells (VSMC) functions as an inhibitor of vascular calcification 
[10]. MGP function depends on the enzymatic carboxylation of specific Glu residues 
converting them to γ-carboxyglutamic, a much stronger calcium chelator. Nonetheless, the 
specific molecular mechanisms linking altered PTMs with the development of 
atherosclerosis, have not been elucidated. Thereby, it is essential not only to develop 
bioinformatics tools that improve PTMs identification and quantitation, but also to apply 
them to the comprehensive PTM proteomics analysis in a model of atherosclerosis to gain 







This work has two main objectives. The first goal is to improve Open-search-based PTM 
identification and quantitation strategies by developing tools that would enable: 
 
• to reduce the artefactual sources of Δmass histogram complexity; 
• to increase the accuracy in the localization of the modified site; 
• to carry out quantitative ontology-based PTM statistical analysis. 
 
The second goal is to demonstrate the performance of the newly developed tools to 
perform a comprehensive and unbiased characterization of the plasmatic PTM changes that 
are associated with atherosclerosis in a mouse model. This new knowledge would improve 





























MATERIAL AND METHODS 
 
Dataset 
The dataset used to analyze PTMs was a high-throughput proteomic study from an ongoing 
project in the laboratory with mice plasma labelled with TMT and searched with 
CometPTM [23]. Male LDLR-KO pro-atherogenic mice were and fed with a normal diet 
(CHOW) or a high fat diet (HFD). At 16 weeks of age, blood was obtained. Samples 
digestion was performed using the filter-aided sample preparation digestion kit (FASP, 
Expedeon) as previously described [24], considering minor modifications [23], with 
trypsin and labelled using 10 plex- TMT reagents according to manufacturer’s instructions 
(Thermo Fisher Scientific TM) [23]. After MS, the raw files were searched with 
CometPTM  [2] with some modifications: trypsin digestion with 2 missed cleavages, +-500 
Da precursor ion tolerance and 0.02 Da fragment ion tolerance. TMT labeling 
(+229.162932 Da) at peptide N-terminal and Lys, as well as Cys carbamidomethylation 
(+57.021 Da) were selected as a fixed modifications [23]. CometPTM output files were 
used as input files for a pipeline composed by the modules developed by Andrea Laguillo 
and Rafael Barrero (ongoing PhD Thesis), DMCalibrator, DMModeller, PeakInspector, 
PeakSelector, PeakAssignator modules can be downloaded from https://github.com/CNIC-
Proteomics/SHIFTS-4. 
Development of Bioinformatic tools 
FDRFilterer, DM0Solver, TrunkSolver, PDMTableMaker, SiteSolver and Sticker modules 
were implemented in Python 3 and can be used in both Windows and Linux operating 
systems. It is currently compatible with conventional LC-MS/MS data and can be used 
with common proteolytic enzymes (including trypsin and Lys-C).  
FDRFilterer  
FDRFilterer filters FDR according to the conditions set by the user, in the configuration 
file.   
  
Input files:  
• .tsv  
• Configuration file (.ini). Default configuration file can be modified by user. 
o FDRFilterer parameters:          
§ GlobalThres:  global FDR threshold. Maximum Global FDR. 
§ PeakThres: peak FDR threshold. Maximum Peak FDR. 
§ LocalThres: local FDR threshold. Maximum Local FDR. 
§ GlobalFDR_column_name: name of the column containing Global 
FDR values. 
§ PeakFDR_column_name: name of the column containing Peak FDR 
values. 
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§ LocalFDR_column_name: name of the column containing Local 
values. 
§ Label_column_name:  name of the column that indicates label. 
§ decoys_naming:  parameter that indicates how decoys are named. 
  
Output files:  
• FDRFilterer output (default suffix: “FDRFilterered”)  
• A log file (default suffix: " FDRFilterered_logFile")  
 
DM0Solver  
DM0Solver is a module that detects whether a modified peptide, termed as pdm (a peptide 
form defined by peptide sequence, Δmass and position) from here on, has 
a Δmass belonging to a list provided by the user (Table 1), for that purpose relative error 
(ppm) is calculated. In such a case, the Δmass is appended at the end of the clean 
sequence (new output column). The corresponding label and the error generated selecting 
that label are added in two additional columns (Table 2). If the Δmass does not belong to 
the list, the module passes the modified sequence without any modification to the output 
columns (Figure 1A). To carry out these tests, the relative error (ppm) must be calculated:  
 
DM0Solver needs the following input files:  
• .tsv file 
• Configuration file (.ini), a default configuration file that can be modified by user, 
containing: 
o DM0Solver parameters:  
§ Relative_Error_ppm: relative error (ppm) allowed. 
§ Exp_mh_column_name: calibrated experimental mh column name.  
§ Theo_mh_column_name: theoretical mh column name.            
§ Sequence_column_name: sequence with Δmass column name.  
§ DM0Sequence_output_column_name: column name of the output in 
which the selected sequence is annotated. 
§ DM0Label_output_column_name: column name of the output in which 
the chosen label is annotated. 
§ DM0Label_ppm_output_column_name: column name of the output in 
which the calculated error in ppm is annotated. 
§ output_file_suffix: chosen suffix for output file. 
  
o DM0Solver list (list of masses with their corresponding label): 
An example of input list for DM0Solver configuration file can be observed in 
Table 1. The first column shows examples of labels ( DM0 for zero Δmass, or 
DM0;C13 for carbon 13 Δmass), while the second column contains de mass in 
Da of each label. DM0Solver uses this list to assign a label, as long as it meets 
the error threshold. 















It delivers two output files:  
• DM0Solver output (default suffix: “DM0S”)   
o New columns (Table 2):  
§ DM0Sequence: output column in which the reassigned sequence is 
annotated. 
§ DM0Label: output column in which the selected label is annotated. 
§ DM0Label_ppm:  output column in which the error, that is obtained 
selecting the label, is annotated. 
• A log file (default suffix: "DS_logFile")  
 






TrunkSolver detects whether the Δmas, in a pdm element may be explained by the 
truncation of a non-modified peptide inside the sequence of the corresponding protein or, 
by a truncation and the presence of a Δmass belonging to a list provided by the user (Table 
3), for that purpose relative error (ppm) is calulated. In such a case, the Δmass is appended 
at the end of the clean sequence (“TrunkSequence” output column), while the 
corresponding label and the recalculated Δmass are added in additional 
columns named “TrunkLabel” and “TrunkDM”, respectively. If TrunkSolver is unable to 
explain the Δmass by a truncation, then it passes the modified sequence and its 
original Δmass without any modification to the output columns. In both cases five extra 
columns(“New_DM”,“New_Theo_mh”,“Match_number”,“Possible_option”, “Trunk_stats






Na adduct 21.981943 
Ammonium_ adduct 17.026549 
H20_loss -18.010565 
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the correct peak assignation (Andrea Laguillo ongoing PhD Thesis) (Table 4, Figure 1 




TrunkSolver needs as input files:  
• .tsv file  
• .fasta file  
• MassMod.ini. Default configuration file can be modified by user. 
• Configuration file (.ini). Default configuration file can be modified by user:  
o TrunkSolver parameters:  
§ Relative_Error_ppm: relative error (ppm) allowed. 
§ Exp_mh_column_name: calibrated experimental mh column name. 
§ Theo_mh_column_name: theoretical mh column name.            
§ Sequence_column_name: sequence with Δmass column name. 
§ Calibrated_Delta_MH_column_name: calibrated Δmass mh column 
name. 
§ MasterProtein_column_name: master Protein column name. 
§ static_modifications_column_name: static modifications column name. 
§ Decnum: decimals points required in TrunkSequence column. 
§ X:  number of positions to the right and left, that the TrunkSolver is 
allowed to extend from the original Δmass site. 
§ New_Deltamass_output_column_name: new Δmass column name. 
§ New_Theo_mh_output_column_name: new theoretical mh column 
name. 
§ TrunkSequence_output_column_name: column name of the output 
where the chosen sequence is annotated. 
§ TrunkDM_output_column_name: column name of the output where 
the recaulcutaed Δmass is annotated, taking in to account the label.   
§ TrunkLabel_output_column_name: column name of the output where 
the chosen label is annotated. 
§ TrunkLabel_ppm_output_column_name: column name of the output 
where the calculated error in ppm is annotated. 
§ Static_modifications_position_output_column_name: column name of 
the output where the new fix modifications positions are annotated   
§ Matchnumber_output_column_name: column name of the output 
where possible options number is annotated. 
§ Possible_option_output_column_name: column name of the output 
where all possible options. 
§ output_file_suffix:  chosen suffix for output file. 
  
o TrunkSolver list (list of masses with their corresponding label).  
!"#$%&'"	"))*)	(,,-) = $01((2ℎ"*)"%&4$#	-$11 + 67,")&-"8%$#	-$11	) ∗ 10000002ℎ"*)"%&4$#	-$11 + <$0"#	-$11 ) 
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An example of input list for TrunkSolver configuration file can be observed in 
Table 3. The first column shows examples of labels, TMT: Δmass of tandem 
mass tag, 2TMT; two Δmasses of tandem mass tags,-TMT: minus Δmass of 
tandem mass tag, ,-2TMT: minus two Δmasses of tandem mass tags. The 
second column contains de mass in Da of each label. TrunkSolver uses this list 
to assign a label, as long as it meets the error threshold. 
 
 
Table 3. Example of input list for TrunkSolver configuration file 






TrunkSolver delivers the following output files:  
• TrunkSolver output (default suffix: “_TS”)  
o New columns (Table 4):  
§ TrunkSequence: output column name in which reassigned sequence is 
annotated 
§ Trunk_DM:  output column name in which recalculated Δmass taking 
in to account the labels. 
§ Trunk_Label: output column name in which the selected label is saved.  
If the Δmass corresponds to a combination between one of the labels in 
the configuration file and a cut, the type of cut also will be noted 
(Figure1 B, Table 4). The label will be TrypticCut if the choice of label 
involves a tryptic cut of the sequence, or a Truncation if it involves a 
non-tryptic cut. 
§ Trunk_Label_ppms: output column in which the error, that is obtained 
selecting the label, is annotated. 
§ New_Theo_Mh: output column name in which the recalculated 
theoretical mass is annotated. 
§ New_DM: output column name in which the recalculated Δmass is 
saved. 
§ Trunk_stats_mods:  output column name in which the new static 
modifications positions are saved, since with the changes in the 
sequence this could vary. 
§ Match_number: output column name in which the number of possible 
options allowed by TrunkSolver is annotated.  
§ Possible_options: output column name in which all possible 
options allowed by TrunkSolver are annotated 
• A log file (default suffix: "TS_logFile")  
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PDMTableMaker, SiteSolver  
 
PDMTableMakertMaker is an independent, but necessary, module for the 
proper operation of SiteSolver.  PDMTableMaker contains the frequencies of the different 
sequence species (pdm) which allows SiteSolver to choose when there is a tie between two 




PDMTableMaker calculates the scan frequency which is used by SiteSolver but also some 
parameters that will allow to build the necessary relations files for the subsequent 
processing of the results by the statistical quantitation workflow, as it will be later 
explained:  p, q, pdm, pd, d, Theo_mh, ScanFreq, a, m, n, l, qna, qdna, A, M, L, N, qdNA 
(Table 5).  
 
PDMTableMaker input files:  
• tsv file. 
• .fasta file.  
• Configuration file (.ini). Default configuration file can be modified by user:  
o PDMTableMaker parameters:  
§ Sequence_column_name:  Sequence that contains the Δmass colum 
name. 
§ DM_column_name:  Δmass column name.  
§ Theo_mh_column_name: Theoretical mh column name.   
§ MasterProtein_column_name:  Master Protein column name. 
§ output_file_suffix:  Chosen suffix for output file.  
o PDMTableMaker conditions:   
§ number_of_conditions: Number of conditions considered.  
§ Conditioni:  Column name of condition i.   
§ Valuei: Chosen value for condition i. 
The program can use as many conditions as it is desired, considering that a 
match will be made between the conditioni and the valuei.  
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PDMTableMaker delivers two output files:  
• PDMTableMaker output (default suffix: “PDM”). An example can be seen in Table 
5. 
o New columns:  
§ p: peptide. 
§ pdm: peptide form defined by peptide sequence, Δmass and position. 
Ex: ABCD[xxx]EFGHK. 
§ pd: ABCEDEFGHK:XXX (includes a set of pdm elements, do not 
confound with ABCEDEFGHK_XXX, which is a pdm, not a pd)  
§ m: position in peptide. Ct (C-terminal) =-1, Nt (Nterminal)=0.  
§ l: position in peptide, from right to left. Ct=,0 Nt = -1. 
§ n: position in protein. Ct =length peptide plus 1, Nt = 0. 
§ a: modified aminoacid. Ct = U, Nt = U. 
§ q: protein identifier. 
§ M: it is the m corresponding to the pdm with highest original PSM 
frequency in a pdm table. 
§ L:   l which corresponds with the razor m. Razor l, property of a pd. 
§ N:  n which corresponds with the razor m. Nt=0. Razor n, property of a 
pd. 
§ A:  a which corresponds with the razor m. Razor a, property of a pd.  
§ qdna: information of q,d,n,a (ex: HPT:yyy:300:M)  
§ qna: information of q,n,a (ex: HPT: 300:M)  
§ qdNA: razor qdna, property of a pd  
§ Theo_mh: Theoretical mh   
§ ScanFreq: Scan frequency  
  
• A log file (default suffix: " PDM_logFile")  
 





SiteSolver is a module made with the aim of detecting if a modified peptide has 
its Δmass in an incorrect position. In such a case, Δmass location within the sequence is 
corrected in the “SiteSequence” column.  If the module does not find any possible position, 
it passes the modified sequence without any modification to the output column. Foremost, 
it is ascertained whether the amino acid position, in which the Δmass is originally located, 
is prohibited. This is tested up using the frequency chosen in the PrimaryList file 
(PrimaryList_colum_name) and ScanFrequency of PDMTableMaker ouput file. From the 
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lists, the mass with the lowest relative error of place will be chosen.. If the amino acid is 
allowed, for that Δmass, it passes the modified sequence without any modification. If the 
amino acid is prohibited, SiteSolver will analyze the contiguous amino acids to that 
position. Provided that only one of them is prohibited the sequence will be corrected by 
assigning the Δmass to the amino acid that is allowed, according to PrimaryList or 
SecondayList file. If both are allowed, for that Δmass, the position with the highest 
frequency in the PDMTableMaker output file is chosen, but if the frequencies are equal, it 
will be taken into account the order of appearance in the PrimaryList or 
SecondayList file. If none of the amino acids are allowed, the contiguous, at each end, will 
be analyzed. The process is repeated until the number of positions to be analyzed, on each 
side, exceeds the maximum (X parameter) (Figures 1 D,E,F,G). To carry out these tests, 




SiteSolver needs the following input files:  
• .tsv file. 
• PDMTableMaker output file. 
• PrimaryList.txt file (user). 
• SecondaryList.txt file (unimod).  
  Secondary and Primary lists will contain 3 columns:   
1) DM: first column must contain the Δmass. 
2) Residue:  second column must contain the residue. In case of N-
terminal and C-terminal, must appear, NT and CT respectively. 
• Configuration file (.ini). Default configuration file can be modified by user:  
o SiteSolver parameters:          
§ Relative_Error_ppm: relative error (ppm) allowed. 
§ Theo_mh_column_name:  theoretical mh column name.    
§ Sequence_column_name: sequence with Δmass column name.  
§ cal_Dm_mh_column_name: calibrated Δmass MH name. 
§ PeakNaming: Parameter that indicates how peaks are named. 
§ PeakAssignation_column_name: name of column that contains peak 
assignation. 
§ x: parameter that indicates the extension (left and right) from the 
original DM site of the amino acid positions to be analyzed. 
§ MinScanFreq: parameter that indicates the frequency threshold for 
PDMTableMaker output file.  
§ MaxNSite: parameter that indicates the number of amino acids allowed 
when the PDMTableMaker output file is analyzed. 
§ PrimaryList_column_name: column name from Primary List wanted to 
be used for SiteSolver. 
!"#$%&'"	"))*)	(,,-) = $01((2ℎ"*)"%&4$#	-$11 + 67,")&-"8%$#	-$11	) ∗ 10000002ℎ"*)"%&4$#	-$11 + <$0"#	-$11 ) 
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§ SecondaryList_column_name: column name from Secondary List 
wanted to be used for SiteSolver. 
§ SiteCorrection_PrimaryList_label: SiteCorrection when the SiteList 
selected is from the Primary list. 
§ SiteCorrection_SecondaryList_label: SiteCorrection when the SiteList 
selected is from the Secondary list. 
§ SiteSequence_column_name: column name of the output in which the 
sequence is annotated. 
§ SiteCorrection_column_name: column name of the output in which the 
correction site is annotated, 
§ SiteOption_column_name: column name of the output in which the 
different possible options are annotated. 
§ SiteDM_column_name: column name of the output in which the 
selected Δmass is annotated. 
§ SiteDMError_ppm_column_name: column name of the output where 
the error of the selected DM is annotated. 
§ Output_file_suffix: chosen suffix for output file.  
  
SiteSolver delivers two output files:  
• SiteSolver output (default suffix: “SS”)  
o New output columns:   
§ SiteSequence: sequence with the Δmass. 
§ SiteCorrection: initial residue (position that has been displaced) and 
final residue. 
§ SiteOption: if there is a tie, which are all the possible options. 
 




Sticker is a module that for each experimental Δmass detects,by calculating the relative error 	
the closest theoretical one from a DMID_list  file . This file will contain some conditions and 
labels. When comparing PDMTabelMaker output file with DMID_list, all the conditions 
established in DMID_list, the labels and the error that produces the corresponding label 
selection, will be annotated in new columns. To do so, the relative error will be calculated:  
 
 
As input files Sticker requires:  
• PDMTableMaker output file  
• DMID_list.txt: 
o Column names:  
§ d:  Column with the Δmass. 
!"#$%&'"	"))*)	(,,-) = $01((2ℎ"*)"%&4$#	-$11 + 67,")&-"8%$#	-$11	) ∗ 10000002ℎ"*)"%&4$#	-$11 + <$0"#	-$11 ) 
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§  Cond_:  all columns with the conditions that must be met, should start 
with “Cond_a_”. If “a” has to be met, a column named “Cond_a” must 
appear in he DMID_list.txt file. It should be noted that the columns 
denoting conditions must include after the prefix "Cond_" (condition), 
names of the columns present in PDMTableMaker, for instance 
"Cond_d", "Cond_p", "Cond_pdm". If the indicated parameter is not 
found in the PDMTableMaker file, the comparison will not be possible. 
The name of the columns that contains the label to be added will begin 
with the prefix "Lab_". 
 
The label for those rows that do not have any label will be specified at 
the first line of the DMID_list file. All columns will be empty except 
for the first column that will start with “Lab_” (Figure 1 G). 
 
• Configuration file (.ini). Default configuration file can be modified by user:  
o Sticker parameters:  
§ Relative_Error_ppm: relative error (ppm) allowed. 
§ Theo_mh_column_name: theoretical mh column name.     
§ Sequence_column_name: sequence with Δmass column name.  
§ Selected_DM_column_name: selected Δmass column name. 
§ StickerLabel_User_output_column_name:  column name of the output 
where the chosen label is annotated. 
§ StickerLabel_ppm_User_output_column_name: column name of the 
output where the calculated error in ppm for the selected label is 
annotated.   
§ output_file_suffix:  chosen suffix for output file.  
  
It delivers two output files:  
• Sticker output (default suffix: “Sticker”):  
o New columns:  
§ StickerLabel: selected label from the user file. It will appear as many 
StikerLabel columns as “Lab_” columns appear in DMIDlist file.  
§ StickerLabel_ppm: relative error calculated with the mass of the 
selected label from the user file. It will appear as many 
StikerLabel_ppm columns as “Lab_” columns appear in DMIDlist file. 
• A log file (default suffix: "Sticker_logFile"). 
 
Workflow 
CometPTM output files were used as input files for a pipeline composed by the modules 
developed by Andrea Laguillo and Rafael Barrero (ongoing PhD Thesis), as well as by the 
ones developed in this work. First the modules developed before this work: DMCalibrator, 
DMModeller, PeakInspector, PeakSelector, PeakAssignator, PeakFDRer were executed,  
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and then the modules developed in the present work  FDRFilterer, DM0Solver, 
TrunkSolver, PeakAssignator  again as it has been explained, PDMTableMaker, 
SiteSolver, PDMTableMaker and  Sticker (Fig. 1H). Note, that when PDMTableMaker is 
executed the second time, it takes as input the SiteSolver corrected pdms. The 
configuration files containing the parameters used to execute all the pipeline can be found 
in Supplementary  Tables 1-12 and Supplemenatry Lists 1-5. 
Quantitative statistical analysis  
The output files from SiteSolver and the PDMTable file from the second round of 
PDMTableMaker were used as input files for the quantitative statistical pipeline (Fig1H). 
To that end, for each scan from the SiteSolver output file the quantitative information from 
the TMT reporter intensities was extracted from the Quant_PSM.txt files previously 
generated by Proteome Discoverer (2.1, Thermo Scientific) during my previous Master 
Thesis [23], appended to the SiteSolver output file and the log2ratios (Xqps) as well as the 
scan weights (Vqps) were calculated [16,17,24-26]. Briefly, for each sample i, the values 
xqps=log2 Ai/C  were calculated, where Ai is the intensity of the TMT reporter of the 
corresponding sample i in the MS/MS spectrum s coming from peptide p and protein q, 
and C is the average intensity of all the TMT reporters from the control samples. The 
SiteSolver output file was used to produce the scan-to-pdm relations tables. On the other 
hand, the PDMTable file was used to build the pdm-to-protein, the pdm-to-
protein_site_DM (qdna) and the qdna-to-protein_site (qna) relations tables.  
The quantitative information was integrated from the spectrum level to the pdm and then to 
the protein level on the basis of the WSPP model [16] using the Generic Integration 
Algorithm (GIA) [27]. Additionally, the algorithm was modified to include the integration 
of the normalized-by-protein pdm (q_pdm) quantitation to the protein_site_DM level 
(q_pdm2qdna), then to the protein_site level (q_qdna2qna), and finally, qdna and qna 
levels were integrated to the experiment Mean (All) (q_qdna2ALL and q_qna2ALL). All 
the integrations were performed as a part of an automated workflow (Figure 1 I), The 
software for statistical analysis of quantitative data can be downloaded from 
https://github.com/CristinaDevesaA/TFM  
Computational services 
Some PTMs identified were checked in the following public PTMs DB: CarbonylDB [28], 
GlyConnect [29], SwissPalm [30], PhosphoSitePlus [31], UniCarbKB [32], iPTMnet [33]. 
ΔM annotation has been performed according to a user curated DB (Ileana Beatriz 
González ongoing PhD Thesis and the Unimod DB [34]. All the developed tools can be 






The following results were obtained by applying the developed tools to a high-throughput 
TMT proteomics experiment in order to characterize PTM in atherosclerotic mouse model 
plasma proteins. 
FDRFilterer 
As described in the Materials and Methods section, first the Δmasses were calibrated, 
peak-modelled and global, local and peak FDRs were calculated using the programs 
developed by Andrea Laguillo  and Rafael Barrero (PhD Thesis in progress) (Figure 1H 
from Materials and Methods). The resulting text files contained all spectra coming from 
target and decoy proteins regardless of their FDR values. Thus, to be able to filter out non-
reliable identifications in a fast and automatic way, we developed FDRFilterer. This 
program can quickly and easily handle several large files at the same time, producing a 
reliable dataset containing only target identifications with controlled FDR values at global, 
local and peak level.  As a result, 217977 of 692215 peptide spectrum matches (PSM) 
passed the established filters.  
DM0Solver and TrunkSolver 
Comet-PTM calculates the experimental mass variation corresponding to a spectrum by 
comparing the theoretical mass, according to the peptide sequence, with the experimental 
mass detected by the mass spectrometer. The following formula is used (Figure 2 A): 
 
∆experimental mass = theoretical mass - experimental mass 
However, during careful data inspection, we realized that a big proportion of non-zero 
Δmasses actually were unmodified peptides (Figure 2B). Among those non-zero Δmasses 
were monoisotopic peak assignment errors, adducts with metals and loss of water and 
ammonia.  
Additionally, many far negative Δmasses, in the overwhelming majority of the cases, had 
as a second candidate for the same scan identical sequence without a partially digested N- 
or C-terminal segment (Ileana Beatriz González Ongoing PhD Thesis). Therefore, many of 
those spectra with far negative Δmasses actually belonged to unmodified peptides that 
were mistakenly assigned by CometPTM to longer peptides. In part, this fact takes place 
due to the score we used to assign the PSM (Xcorr) which is proportional to the number of 
matched fragments [35] and thereby gives preference to larger peptides [36]. This Xcorr-
associated effect is shown in Figure 2C were the Δmass decoy distribution is biased 
towards the negative Δmasses. An additional source of the artefactual far negative Δmasses 
were the unaccounted non-tryptic or semi-tryptic cuts since the search constrained the 
theoretical candidate sequences only to fully tryptic cuts. To resolve these unaccurate 
assignations we developed DM0Solver and TrunkSolver, with the common goal of 
detecting and recovering all those forms of unmodified peptides. Accordingly, DM0Solver 
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was employed to detect adduct formation, isotopomer errors, and water and ammonia 
losses/gains.  TrunkSolver was set to find tryptic and non-tryptic cuts and their 
combinations with TMT losses/gains (a common artifact detected in this kind of isobaric 
labeling experiments).  
We first executed DM0Solver, which for each scan calculated the composite mass of the 
theoretical [M+H]+ plus each one of the Δmasses present in the user configuration file 
(Supplementary Table 4), that apart from Δmass =0,  also included 13C-errors, and some 
metal adducts. Afterwards, the program calculated the ppm mass difference between this 
composite mass and the calibrated experimental mass [M+H]+. If the obtained ppm was 
below the user specified threshold (10 ppm in this case), the PSM was labelled by the 
corresponding Δmass from the configuration file. Furthermore, since the Δmass could not 
be ascribed to any specific position inside the peptide, the Δmass was appended at the end 
of the clean sequence in a new “DM0Sequence” output column (Materials &Methods 
Table 2). Otherwise, the modified peptide sequence was passed unchanged, and was used 
as input for TrunkSolver (Materials &Methods Figure 1H). Thus, to preserve DM0Solver 
results, TrunkSolver only considered peptide sequences from the “DM0Sequence” column 
with the Δmass in brackets, while the ones produced by DM0Solver were passed 
unchanged (Table 4 and Figure 1 H from Materials &Methods). 
 
As it is schematized in Figure 1B from Materials and Methods, on the basis of the 
“DM0Sequence” and the corresponding protein sequence from the fasta file, TrunkSolver 
tested all possible tryptic and non-tryptic cuts and the combination with each one of the 
Δmasses set in the configuration file (Supplementary 5). For each one of these 
combinations, TrunkSolver chose the one that resulted in the lowest relative error as long 
as it was below the threshold established in the configuration file (10 ppm in the present 
work). The precursor tolerance used during the search was +-500 Da , the mean mass of an 
amino acid residue is around 100 Da, that is why the number of residues considered by the 
program (“x” parameter) were up to six positions away from the original Δmass site to the 
right or to the left. Thus, to reveal possible semi-tryptic or non-tryptic cuts, TrunkSolver 
tests were also extended beyond the peptide sequence N- or C-terminal and into the fasta 
protein sequence. If all the above-mentioned conditions were met, the new clean sequence 
with its new experimental Δmass appended at the end (the Δmass position becomes 
unknown), was annotated in the new “TrunkSequence” column. Moreover, if the 
removed/added segment of the sequence implicated a partial digestion, it was labelled as 
“tryptic cut” in the TrunkLabel column, while if it was a non-tryptic cut, it was labelled as 
“truncation”. However, if TrunkSolver was unable to explain the Δmass, it passed the 
modified sequence and its original Δmass without any modification to the output columns. 
Therefore, when TrunkSolver changes the theoretical mass, it concomitantly changes the 
experimental Δmass. For this reason, and to re-establish the correct Δmass-to-peak 
assignment, it is necessary to run again PeakAssignator (Andrea Laguillo Barrero ongoing 
PhD Thesis) using the new columns produced by Trunkolver: TrunkSequence, New_DM 
and New_Theo_mh (Table 4 and Figure 1 H from Materials &Methods).  
 
19  
After using DM0Solver and TrunkSolver, 48.78% of the spectra (106326 of 217978) were 
recovered as unmodified peptides: 36.47% by DM0Solver and 12.31% by TrunkSolver 
(Figure 2 D and E). Of the percentage tagged by DM0Solver, as expected, most of the 
Δmasses (70.39%) were equal to zero. However, this tool also recovered an important 
additional 22.67% of the spectra related to 13C errors (18.44%, 3.33% and 0.90% 
belonging to one, two and three 13C, respectively) and a 1.19% to water loss. There was 
also a percentage of 5.75% pertaining to adducts, specifically 1.60% to sodium adducts, 
2.97% and 1.18% gains and losses of ammonium adducts, respectively (Figure 2D). 
 
On the other hand, attending to the percentage recovered by TrunkSolver, as expected, the 
vast majority (45%) were scans coming from peptides reassigned to the Δmass=0 peak due 
to tryptic cuts, and a minor proportion (9%) corresponded to non-tryptic cuts that were also 
reassigned to the Δmass=0 peak. In other matters, the 39.66% was related to TMT-gain 
(32.99% TMT without partial digestion, 4.33% TMT and tryptic cut and 2.34% TMT and 
non-tryptic cut). Moreover, a 3.63% was related to TMT-losses (1.94% TMT-loss without 
partial digestion, 1.68% TMT-loss and non-tryptic cut and 0.01% TMT-loss and tryptic 
cut.). 2.59% of cases were related to the double gain or loss of TMT (1.57% double gain of 
TMT, 0.49% non-tryptic cut and double gain of TMT, 0.46% double loss of TMT with 
tryptic cut, 0.06 % double loss of TMT and non-tryptic cut and 0.01% double loss of TMT) 
(Figure 2E). 
 
The performance of DM0Solver and TrunkSolver is shown in the Figure 2F, where the 
Δmass peak frequency difference between PeakAssignator2 and PeakAssignator1 is 
presented. That is, after using DM0Solver and TrunkSolver (PeakAssignator2) compared 
to the original situation before using DM0Solver and TrunkSolver (PeakAssignator1), the 
intensity of Δmasses peaks in the negative zone is drastically reduced and we recover a lot 
of unmodified and extra TMT-labelled peptides, as well as peptides lacking one TMT 
moiety. The most prominent negative Δmasses decreasing were -357.259079Da and -
156.102444 Da. Those ∆masses correspond to an extra lysine labelled with TMT and to an 
extra arginine, respectively, and were recognized as non-modified peptides by 
TrunkSolver. In addition, the frequency of +229.162932 Da Δmass increases owing to 
many peptides getting cleaned from their extra sequence segments due to the Xcorr effect, 
and this uncovers the TMT mass.  
 
PDMTableMaker and SiteSolver 
Comet-PTM automatically assigns the modification to the residue in the peptide sequence 
that produces the best score and that best explains the fragmentation data. Assigning 
modifications to specific residues is considered a much less reliable process than 
identifying peptides, partly because there is frequently insufficient information to 
determine the exact modified residue [37]. Consequently, one out of five of the sites are 
misallocated [2], leading to data dilution during modified peptide quantitation and loss of 
statistical power to detect changes. Thus, the goal of SiteSolver is to detect the wrongly 
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assigned modified residue, and to relocate them to the most probable allowed site (Figure 
2G) 
For each experimental Δmass SiteSolver selected the allowed sites first from a user-curated 
list of theoretical Δmasses and their corresponding modifiable residues (See 
Supplementary Lists, 1,2 , Figure 1H from Materials &Methods), using a user-defined ppm 
mass error (<10 ppm in this work) calculated as described in the Materials and Methods 
section. Note that at this stage, only experimental Peak Δmasses should be used (Figure 1H 
from Materials &Methods), which should be properly specified in the 
PDMTableMaker_Conditions (Supplementary Table 7, Figure 1G from Materials 
&Methods). If the peak Δmass was not found in this Primary list, it was checked in the 
Secondary list coming from Unimod (See Supplementary List 2 and Figure 1G from 
Materials &Methods). Thus, if for a given sequence the peak Δmass was situated on an 
allowed residue, it was kept there and the sequence was passed unchanged to a new 
“SiteSequence” column. However, if it was found on a forbidden residue, it was moved 
towards the closest allowed residue for that peak Δmass and in the “SiteSequence” column 
the sequence appeared with the Δmass in the new position (Figure 1D from Materials 
&Methods). Also, to allow the user to review this delicate process, the modified residue 
change was annotated in the “SiteCorrection” column together with the corresponding list 
from which the allowed site for that Δmass was selected. In addition, the calculated Δmass 
error (ppm) was reflected in the “SiteDMError_ppm” column. However, in many cases 
there are more than one allowed residue in the same sequence, and both could be true 
(Figure 2G). Thus, to keep both possibilities we introduced the parameter X, that limited 
the number of residues away from the original position that a Δmass could be moved to 
reach an allowed residue (Figure 2G). In such cases, when for a given peptide the Δmass is 
dispersed forming two distributions around the two possible allowed residues, thanks to the 
constrains given by the X parameter on the SiteSolver working range, the Δmass can be 
concentrated on the two specific sites for that peptide (Fig.2G). In addition, there are cases 
where in the same sequence the two allowed residues are at the same distance from the 
original prohibited Δmass site. To decide to which one of them to assign the given Δmass, 
we checked for that sequence, which site with the given Δmass had the highest number of 
spectra and that information was given by the PDMTableMaker program (Figure 1E from 
Materials &Methods). Finally, if the peak Δmass was found on a forbidden residue and 
there were no allowed residues in the peptide sequence fulfilling the X parameter working 
range, the pdm was passed to the “SiteSequence” column unchanged and the 
“SiteDMError_ppm” column was left blank. 
To test the efficiency of SiteSolver we represented the percentage of relocations in terms of 
the number of residues apart from the original Δmass site (Figures 2H and 2I). Figure 2H 
was created setting the program parameter X equal to fourteen, so that the modification 
cannot be relocated more than fourteen residues away from the original site. As a result, 
and taking all peak Δmasses together (Figure 2H), the highest percentage of relocations 
takes place in the amino acid contiguous to the original site and so progressively until only 
the minority are repositioned further away. As a matter of fact, this is corroborated for 
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important modifications such as deamidation, phosphorylation and oxidation (Figure 2 I), 
for which corrections are made more frequently in the closest residues. The more 
SiteSolver moves away from the original site, the lower is the number of peptides that are 
repositioned, being the percentage difference between “x” equal 1 an “x” equal two less 
accentuated in phosphorylation. On the bases of these results, the analysis from there on 
were performed setting the parameter X equal to three. (Suppementary Table 8) 
Sticker 
The PTM analysis, after running DM0Solver, TrunkSolver and SiteSolver, results in a long 
list of Δmasses which are usually interpreted by databases such as Unimod. However, this 
way of analyzing has its drawbacks. For instance, Unimod neither contains frequent Δmass 
combinations, for example oxidation plus deamidation (15.994915 + 0.984016 = 
16.978931 Da), nor Δmasses resulting from incompatible chemical reactions with the fixed 
modifications set during the search: for example, a pre-existing acetylation would hinder 
TMT labeling, resulting in a Δmass not found in Unimod (42.010565 - 229.162932 = -
187.152367 Da). Moreover, some Δmasses with biological relevance, previously detected 
in the laboratory, are not in this database [2]. In parallel, it must be considered, that there 
are isobaric Δmasses with radically different chemical nature depending on the residue 
they are located on. For instance, 15.994915 Da can be oxidation or amino acid 
substitution (A->S), while 0.984016 Da can be deamidation or amino acid substitution 
(Asn->Asp or Gln->Glu). Finally, Unimod actions are only available for certain organisms. 
 
Hence, for a given experimental Δmass, Sticker annotations are not only based on the 
relative mass error threshold not being exceeded (in the case of this work 10 ppms), but 
also on the residue being modified, and if it appears for that Δmass in any of the provided 
lists. In this way, from the lists based on artifacts, Unimod and the user curated database, 
Sticker labelled the 84,59% of the modifications. (Supplementary Tables 10-12  and 
Supplemnetary Lists 3-5) 
 
Quantitation and statistical analysis workflow 
We previously developed an algorithm based on an accurate and robust statistical model 
(WSPP) [27] that used an automated workflow for the simultaneous PTM, protein and 
systems biology quantitative statistical analysis [2,16,38]. The algorithm executed a 
peptide-to-protein integration to quantify protein values and then computed the 
standardized log2-ratio of the modified peptides with respect to these protein values (Zpq). 
That allowed the detection of modified peptides with a behavior deviating more than 
expected (FDRpq<5%) from the rest of the peptides from the same protein, independent of 
the changes in protein abundance. However, at that time there were no tools to classify 
PTM into categories, which hindered a system-wide analysis of PTMs. Here, in the output 
from PDMTableMaker, all pdms are presented in a handy way with plenty information in 
separate columns to easily classify pdm according to, for instance, the type of residue being 
modified, the ∆mass, the clean peptide sequence, among other parameters (Table 5 from 
Materials & Methods). However, in this work we focused on the pdm classification 
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according to the protein site being modified by a given ∆mass (qdna) or by groups of 
∆masses (qna), since this kind of PTM grouping could automatically reveal the specific 
protein sites involved in a given biological model with a single PTM or a whole 
modifications pathway.  
 
Biological results 
The performance of the developed tools is presented by a comprehensive characterization 
of PTMs induced by high-fat diet in plasma from an atherosclerosis mouse model.  
The comparative pdm profile revealed clear differences between atherosclerotic and 
healthy mice. The increased pdms were specifically concentrated in APOE, ALBU, APOB, 
APOA2, HPT, APOA1, D3Z5G7, A1AT5 and MUG1 (Figure 3A). APOE was the protein 
that accumulated most of the increases (50.78%), mainly due to Met and Pro monoxidation 
(60.18%), but also to dioxidation (16.66%) at unknown residues, replacement of 2 protons 
by calcium (13.31%) and Trp oxidation to dihydroxy-N-fomaylkynurenine (9.90%). 
albumin from atherosclerotic mice presented more DTT-resistant Cys oxidations in the 
form of sulfinic and sulfonic acids. Finally, APOA1, APOB and HPT had higher Trp 
oxidation to hydroxykynurenine or to dihydroxy-N-fomaylkynurenine, while APOA2 and 
MUG1 showed higher Phe and Met monooxidations. 
At this point, some decreases have also been identified in ALBU, A1AT2 and APOA1, the 
three of them accumulating 59.74% of the decreases (Figure 3B). ALBU mainly with 
di/tri/ and tetraoxidations at unknown amino acids, and sulfonic and sulfinic Cys, among 
others; AIAT2 with Asn deamidation and di/trioxidations, and APOA1 with 
di/trioxidations, Trp oxidations to kynurenine, hydroxykynurenin and dihydroxy-N-
fomaylkynurenine and Met oxidation, among others. 
On the other hand, the analysis at specific modified protein sites (qna) confirmed the 
protagonist role of ApoE in plasma from atherosclerotic mice, although other proteins, 
such as ALBU, HPT, Q58EV2, FETUA, A1AG1, APOA4 and SPA3K were also involved 
(Figure 4A). APOE had higher modification of Met118, mostly in the form of oxidation to 
aspartic semialdehyde (-32.00Da) and monoxidation (15.99Da); of Pro94 in the form of 
oxidation to pyroglutamic acid (13.97 Da and its C13 isotope); and of Trp274 in the form 
of oxidation to hydroxyformylkynurenine (C13 isotopomer with 48.98Da) and 
dihydroxytryptophan (31.98Da). 
Moreover, figure 4B shows decreases mainly in ALBU Tyr419, concentrating a group of 
three modifications, such as trioxidation (49.99Da), phosphorylation (2C13 isotopomer 
with 81.98Da) and at a much lower extent, TMT (229.16Da). In addition, Ala146 decrease 
is related to several Δmasses: -15.02 Da, 46.97 Da, 245.16 Da, 58.01 Da, 30.98 Da, 32.99 
Da, 48.99 Da, 64.98 Da, -31.01Da, -16.02 Da, being the largest decrease in -16.02 Da and 






The aim of the bioinformatics tools developed in this work was to address some of the 
remaining challenges in high-throughput identification and quantification of PTM using 
the open-search approach.  
 
The first challenge was to reduce the misassignment as modified peptides. This was 
accomplished by developing DM0Solver and TrunkSolver. The first one recovers non-
modified peptides from Δmass peaks produced by common MS-associated artefacts such 
as isotopic errors, in-source formation of labile adducts with metals, or water and ammonia 
losses/gains, among others. TrunkSolver, on the other hand, dealed with unaccounted 
semi- and non-tryptic cleavages, which were artifactually detected as false PTM. As a 
result, the Δmass histogram was greatly simplified, especially in the far-negative Δmass 
region and an important proportion of non-modified peptides was recovered (Figure 2F). 
TrunkSolver operation is similar to Crystal-C [39], a computational tool for refinement of 
open search results. Although the differences have to be studied in more depth, Crystal-C 
does not have a variable similar to the “x” parameter of TrunkSolver. As explained in 
Materials and Methods, “x” defines the number of allowed positions to the right and to the 
left from the original Δmass site, extending, in some cases, the peptide sequence beyond its 
termini and into the fasta protein sequence. This is an important factor for a better control 
of the program behavior. Due to the 500 Da constrains on the precursor mass during the 
CometPTM search it is pointless to allow TrunkSolver to inspect positions beyond that 
range established by the user, in the configuration file (X parameter, Supplementary Table 
5), from the original Δmass site. Moreover, the lack of control of the “x” parameter not 
only increases the execution time but is also more error-prone. 
 
 
The second challenge was to correct the localization of the modified residue to the most 
probable site when the information in the MSMS spectrum was not enough to accurately 
pinpoint the site. This was addressed by the combination of the programs PDMTableMaker 
and SiteSolver. Here is important to highlight that SiteSolver gives preference to the list of 
allowed residues in the user-curated Δmass file over the ones found in Unimod. In this way 
the user-accumulated experience in specific modifications prevails over the more general 
Unimod data base information. The scan frequency of each pdm calculated by 
PDMTableMaker is used by SiteSolver in cases where in the same sequence are two 
allowed residues at the same distance from the original prohibited Δmass site. Most Δmass 
relocations performed by SiteSolver took place in the residues closest to the original 
modified site. Besides, the Δmass dispersion along the peptide sequence was greatly 
reduced and got concentrated on the most probable site(s) (Figure 2G). These findings 
showed that SiteSolver was effective to resolve the site allocation problem (Figure 2H and 
2I).    
 
The third challenge was to enable quantitative ontology-based PTM analysis. This problem 
was approached by using PDMTableMaker and the new integration steps from our 
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quantitative workflow based on the WSPP [27] statistical model. PDMTableMaker 
allowed the integration of pdms into upper level elements attending to the ∆mass (d), the 
protein site being modified by a given ∆mass (qdna), including the different peptide forms 
that contain the modification, or the modified residue (qna), including all the modifications 
that affect it. These pdm groupings were used as relation tables for new integrative steps in 
the workflow that concentrated the quantitative information, avoiding the “dilution” 
problem and increasing statistical significance, and revealed specific protein sites with a 
single PTM or whole modification pathways associated with atherosclerosis in the mouse 
model used in this work. 
 
All the tools developed in this work were set into a modular pipeline schematized in Figure 
1H from Materials and Methods. We should note that the tools are independent and 
flexible, obviating the need to follow a preestablished order. The user can decide to run all 
the modules in a given order or just part of them, depending on the objective to be 
achieved. The modules can also be run several times in the same workflow if needed. Also, 
by adjusting the parameters in the configuration files (Supplementary Tables 1-12) and 
lists (Supplementary Lists 1-5) the user has full control of the program’s execution.  
 
Taking advantage of the great versatility of the modular design, we decided to develop a 
workflow that would allow us to optimally analyze the PTM data. Thus, we decided to 
execute DM0Solver before TrunkSolver for the sake of time. TrunkSolver takes longer 
than DM0Solver, since it has to make all the combinations between the different cuts of 
sequences and the Δmasses established by the user (Figure1 B, Supplementary Table 5). 
Then, peptides assigned as unmodified by DM0Solver would not have to be reanalyzed by 
TrunkSolver. In this way, the workflow would start with DM0Solver followed by 
TrunkSolver and, as it has been previously explained, the latter must be accompanied by 
PeakAssignator to re-assign the newly generated Δmasses to the corresponding Δmass 
peaks. 
 
On the other hand, we decided to run the combination of PDMTableMaker&SiteSolver 
after the combination of TrunkSolver&DM0Solver, and not before, also for the sake of 
time. First, any reassignments made by the latter two, as the Δmasses are extracted out of 
sequence, would not have to be examined by SiteSolver. Thus, once PDMTableMaker has 
been passed, SiteSolver can be executed, and to finish, with the aim of keeping SiteSolver 
corrections on the peak Δmasses together with orphan Δmasses in a final compact pdm 
table, PDMTableMaker has to be run once again.  
 
Sticker can be used as a final module, with the advantage that it can be run on the 
PDMTable itself, on the SiteSolver output file, as well as on any file containing as a 
minimum requirement the 2 columns (Δmass, residue). Moreover, Sticker was also made 
flexible accepting not only the classical Unimod lists of Δmasses, but also user-curated 
lists from biological Δmasses not found in Unimod, like newly discovered PTM, or 
artefacts derived from a specific chemistry.  
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The tools developed in this work would contribute to understand the interplay between 
PTMs and protein function in the context of disease. To demonstrate it, we applied our 
tools to perform a comprehensive unbiased study of the changes of plasma modified 
peptidome in a atherosclerosis mouse model. This is a pathology underlying many other 
cardiovascular diseases which are the main cause of death worldwide [17]. The role of 
PTMs in this disease has never been studied from a truly hypothesis-free approach, which 
may be indispensable for advancing in atherosclerosis research.  
Our results demonstrate that the development of atherosclerosis brought about by high-fat 
diet in LDLR KO mice is accompanied by altered PTM profiles, especially on ApoE and 
ALBU. Note that in this work we achieved a quite high sequence coverage for both 
proteins: 78% for ApoE and 90% for Albu, which allowed the construction of accurate 
PTM maps of both proteins. Thus, the induction of atherosclerosis brings about a 
significant increase in plasmatic ApoE oxidation pathways specifically on M118 and 
W274. Albu, on the other hand, is more irreversibly oxidized on its C591, while the rest of 
di-tri- and tetra oxidations on difficult to assign residues are reduced.  
Apolipoprotein E is a structural component of all lipoproteins except for LDL (low density 
lipoprotein) and is a critical ligand for the hepatic clearance of plasma lipoproteins 
mediated by LDL and LDLR (low density lipoprotein receptor) [40]. ApoE has been found 
to provide extra atheroprotective properties since it plays a requisite role in remnant 
lipoprotein clearance by the liver, and although hepatic LDL receptors can clear both LDL 
and ApoE-containing lipoproteins, LDL receptor-related protein mediated clearance of 
remnants is dependent on ApoE [41]. Concerning ApoE M118, although one of the PTMs 
taking place on this residue is also a common MS-associated artefact (Met oxidation), it 
co-occurs with an extreme oxidation to aspartic semialdehyde on the same residue. 
Moreover, ApoE has 13 additional Met residues, from which we detected 7. One of those 
(M135) has a known sulfoxidation site differentiating C57BL/6 and BALB/cmouse strains 
[42], which we find decreased. However, from the 6 remaining Met residues, only 
oxidative modifications in M118 were found increased. Altogether, our results suggest that 
the oxidation pathway on M118 from ApoE is truly associated with atherosclerosis. 
There are no functions reported for M118 in ApoE. In the primary ApoE sequence the 
closest known modified sites are quite far from Met118 (K105 ubiquitination and T134 
phosphorylation), and the probability of interference among the three of them seems quite 
low. However, in the 3D structure M118 is situated in an internal position from a α-helical 
region facing the other 3 helixes composing ApoE structure (Figure 5). Moreover, these α-
helical regions contain tandem repeats conserved among ApoA1, ApoA4 and ApoE, 
induce the helical structure of these proteins and afford them the ability to bind lipids [43]. 
In ApoE this region goes from residue 80 until 255 [43] and we find altered other residues 
falling in this region, such as the increasing P94, the already mentioned M135, the 
decreasing E87.  
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P94 oxidation to pyroglutamic acid, a ROS-induced extreme oxidation of Pro [44], is 
increased in atherosclerotic mice compared to the control ones. Moreover, out of 9 ApoE P 
residues, we detect 5, but only P94 is changing, reinforcing its biological nature.  
Contrary to M118, M135 is situated on an external loop linking two α-helical regions 
(Figure 5), which could make this Met more oxidation-prone in vivo, compared to the rest 
of ApoE methionines. However, this M is less oxidized in atherosclerotic mice, suggesting 
there might be other mechanisms involved regulating M135 oxidation. Thus, we speculate 
that all alterations we observe in this conserved α-helical tandem repeat could affect ApoE 
assembly into its helical structure and change the protein ability to bind lipids. 
On the other hand, we also find increased the oxidation pathway on ApoE W274 in the 
form of di and trioxidation. This seems a biologically significant finding since out of the 7 
ApoE W residues, we detect 4 and W274 is the only one changing. Near W274 lies the 
residue E276, which is located on a region concentrating di- and trioxidations, most 
probably situated on nearby residues. Contrary to W274, the rest of the oxidations in this 
protein region are reduced in atherosclerotic mice. W274 and E276 are outside of the 
previously mentioned α-helical tandem repeats. However, they are found in a region 
responsible for the specific association with VLDL (very low density lipoportein). With 
this regard, W oxidations have already been related to atherosclerosis, being the 
kynurenine pathway associated with an increased probability of developing symptomatic 
unstable atherosclerotic disease [45,46]. Thus, we are tempted to speculate that alteration 
of this region my change the ApoE-VLDL union, and may alter the transport of lipids 
synthesized in the liver inside the tissues, as well as the lipase hydrolyzing activity, thus 
giving rise to hypertriglyceridemia and therefore atherosclerosis [47]. 
 
Moreover, oxidations located near ApoE L303 and P305 are decreased. These residues 
belong to an homooligomerization region and their modifications could alter ApoE 3D 
assembly. It has been studied that protein oligomerization generate non-functional proteins 
and form fiber deposits, leading to a large number of degenerative diseases such as 
Alzheimer's, Creutzfeld -Jacob, Parkin- son, Huntington, systemic amyloidosis, type II 
diabetes, amyotrophic lateral sclerosis and cerebral angiopathy, among others [48], but it 
has not been observed in ApoE.  
 
In addition, plasmatic ApoE from atherosclerotic mice is more associated with calcium, 
than in control animals. This is an interesting finding, since calcium gives rise to 
calcification, contributing to the formation of atherosclerotic plaque [49,50], although our 
results are limited to take conclusions in this point. 
 
Albumin, on the other hand, is the most abundant plasma protein with pleiotropic 
functions, ranging from regulation of plasma osmotic pressure, binding and transport of 
various endogenous or exogenous compounds, and finally to extracellular anti- oxidant 
defenses [51]. Lower serum albumin levels are associated with increased risk of 
cardiovascular mortality, coronary artery disease and stroke suggesting protective effects 
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of albumin against atherosclerosis [52]. This phenomenon could be related to the 
antioxidant properties of albumin and to its calcium transporter role [52,53]. Albumin is an 
helicoidal protein, consisting of three structurally similar domains I, II, and III, each of 
them formed by two subdomains (A and B) [54]. Domain II has been confirmed as the 
most rigid one [53]. 
Atherosclerotic animals show a striking decrease in the overall albumin oxidation (di/tri 
and tetraoxidations), which is concentrated mainly on domain I. Of note are C86 and C148, 
which are part of disulfide bridges. The bridge formed between C86 and C77 involves a 
region containing the reduced sites V78, A83, A84 and N85, while C86 is less sulfonated 
in diseased animals. As for C148, it seems to be in a region which is in general less 
oxidized in atherosclerotic animals. Contrasting with these two Cysteines is C591, located 
on domain III as part of a disulfide bond, and whose sulfonated and sulfinated forms are 
increased in the diseased animals compared to controls. The rest of the 31 Cys detected in 
albumin in different modified or non-modified forms, out of the 37 total Cys contained in 
the protein sequence, were not altered. Thus, all the observed PTM changes could be 
related with some albumin function acting as a redox defense mechanism [51] (Figure 6).  
In conclusion, the physiological-mechanistic relevance of the obtained results cannot be 
determined yet since they are novel. There are still many obstacles to overcome in the 
biological field of the disease, as well as in the technological one regarding post-
translational modifications. The detected PTMs could be markers that reflect the 
atherosclerosis, or effectors that are involved in the pathogenesis. Consequently, the need 
to continue our study is evident, not only in the technological part but also in the biological 
one, applying our tools to ongoing projects in atherosclerotic models such as the ApoE KO 
mice (David Sancho laboratory), minipigs (Jacob Fog Bentzon) and clinically-relevant 
projects in humans such as PESA (Progression of Early Subclinical Atherosclerosis) and  
















The main conclusions reached in this study were the following:  
1. DM0Solver and TrunkSolver produced an important simplification of the Δmass 
histogram, especially in the far negative Δmass region, almost doubling the number 
of PSMs assigned to unmodified peptides. 
2. SiteSolver minimized the dispersion of modified residues, concentrating the 
quantitative information on the most probable site(s) 
3. PDMTableMaker and Sticker on one side, and the new WSPP integrative algorithm 
on the other, enabled a quantitative ontology-based PTM analysis, detecting 
alterations of specific protein sites affected by single PTMs or even by whole PTM 
pathways.  
4. The development of atherosclerosis brought about by high-fat diet in LDLR KO 
mice is accompanied by altered PTM profiles mainly on ApoE and ALBU, among 
other proteins. There is a significant increase in plasmatic ApoE oxidation 
pathways specifically on M118 and W274; Albu is more sulfonated and sulfinated 
on its disulfide bond-forming C591 from domain III, while domain I is in general 







































































































































X = all amino acids except P
Z = all amino
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Figure 1.  DM0Solver, TrunkSolver, SiteSolver, Sticker operation and scheme of the integrative 
workflow used to quantify modified peptides. 
 
A) DM0Solver Operation. In the left part of the figure, a scheme of the peptides analyzed by DM0Solver is 
shown. Each peptide has a Δmass (square).  DM0Solver, calculates the relative error with each of the masses 
of the labels introduced in DM0Solver configuration file (right part of the figure). DM0Solver saves the 
lowest error produced and if it is lower than the Relative_Error_ppm parameter, the error is noted at the 
output. 
B) TrunkSolver Operation. At the top of the figure the peptide is represented with its Δmass. This peptide 
sequence is elongated from the modified residue onwards to the right and to the left following the protein 
sequence in the fasta file as many residues as it is set in the x parameter of the configuration file. In this case 
the Δmass corresponds to a cut plus a TMT. This cut can be a tryptic or non-tryptic cut (truncation) 
depending on the amino acids at the C-terminal of the cut. If the cut occurs between lysine or arginine and 
any other amino acid that is not proline, it is a tryptic cut. If the cut occurs between arginine or lysine and 
proline, it is a truncation, and if at the C-terminal end of the resulting peptide sequence there is no lysine or 
arginine, it will be a truncation. The left part of the figure schematically shows, the entire peptide and all the 
possible cuts analyzed by TrunkSolver. TrunkSolver, calculates the relative error with each of the masses of 
the labels introduced in the TrunkSolver configuration file (right part of the figure). TrunkSolver saves the 
lowest error produced, which, in this case, corresponds to a truncation plus a TMT. If the error is lower than 
the Relative_Error_ppm parameter, it is noted in the output file.  
C) Example of SiteSolver operation. A PDM is analyzed to detect if its Δmass is at an incorrect position. 
SiteSolver will consider as many positions as it is set in the configuration file. In a first step, SiteSolver 
checks if the amino acid, to which the Δmass is originally assigned (pink circle), is forbidden or allowed by 
looking in the Primary list. As it does not appear (prohibited), it evaluates the contiguous amino acids (dark 
blue and light blue circles). SiteSolver concludes that one of the two is allowed (light blue circle) in the 
Primary List. Hence, the sequence is reassigned.  
D) SiteSolver operation instance. This PDM analysis follows the same schema. In a first step, SiteSolver 
determines if the amino acid, to which the Δmass is originally assigned (dark blue circle), is forbidden or 
allowed, by looking in the Primary list. As it does not appear (prohibited) it evaluates the immediate amino 
acids (orange, gray circles). The amino acids are not allowed in the Primary list. Accordingly, SiteSolver 
examines to the following immediate amino acids (light blue and green). At this point a tie can be seen since 
both are allowed. In these cases, SiteSolver assigns the Δmass to the aminoacid with the highest scan 
frequency which are obtained from PDMTableMaker output.  
E) Example of SiteSolver operation. After verifying that the Δmass was assigned, in its original form, to a 
forbidden amino acid for that Δmass (dark blue circle), Site Solver tests out the immediate amino acids (gray 
and orange). Considering that both are allowed and have the same scan frequency the order in which they 
appear in the Primary list is decisive. It is assigned to the amino acid that appears first (gray circle). 
F) Example of SiteSolver operation.  This example is similar to D), with the difference that the Δmass is 
not in the Primary list so the SecondaryList is observed. This list shows how the Δmass was assigned, in its 
original form, to a prohibited amino acid for that Δmass (prink circle). Site Solver evaluates the contiguous 
amino acids (blue and lemon green circle). The Δmass is reassigned to the only allowed amino acid (lemon 
green circle). 
G) Sticker operation Instance. An example of a DMID_list.txt is outlined at the top of the figure. The first 
column contains the Δmass, followed by two terms "a" and "m", which are existing fields in the 
PDMTableMaker output file. The fourth and fifth columns are the labels that are assigned. The first row of 
DMID_list.txt always specifies which label must be annotated when the conditions are not met, in this case 
“No_Label”. For each row of the PDMTableMaker output file, if DMID_list.txt terms are met it will be noted 
in the output file. 
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H) Workflow scheme. Dataset was searched with Comet-PTM followed by DMCalibrator, DMModeller , 
PeakInspector, PeakSelector, PeakAssignator, PeakFDRer (Andrea Laguillo ongoing PhD Thesis). 
PeakInspector (Rafael Barrero ongoing PhD Thesis) allows the inspection of the DM histogram to set 
PeakSelector parameters. PeakFDR's output was filtered using FDRFilterer. The filtered ID_PSM table was 
passed to DM0Solver. Then TrunkSolver was run with the fasta file along with the DM0Solver outout. To re-
adjust the DM peaks due to the action of TrunkSolver, PeakAssignator was used again with the apex list from 
PeakSelector and TrunkSolver output files. With the PeakAssignator output file, together with the fasta file 
and considering only peaks, PDMTableMaker, gave rise to the PDMTable. SS took the ID_PSM 
PeakAssignator output file, together with the PDMTable and which served SiteSolver, together with the 
primary and the secondary lists, to correct the wrongly assigned modified sites in the ID_PSMTable. To save 
the peak Δmasses data corrected by SiteSolver together with the rest of orphan Δmasses in the same 
PDMTable, PDMTableMaker was run again on the ID_PSM file output from SiteSolver considering all 
Δmasses, and give rise to a Final PDMTable, which was labeled with Sticker making use of the artifacts, 
Unimod and user lists (Supplementary Lists 3,4,5 respectiveluy). The ID_XV file was obtained by merging 
the ID_PSM file output from SiteSolver with the Quant_PSM files output from Proteome Discoverer 
containing the intensities of the TMT tags. From the ID_XV file the XV_data and scan2pdm relations files 
for the WSPP quantitative workflow were obtained, while the rest of the relations files (pdm-to-protein, the 
pdm-to-protein_site_DM (qdna) and the qdna-to-protein_site (qna)) were obtained from the FinalPDMTable. 
For the correct functioning of the programs, the configuration files (Supplementary tables 1-12) and certain 
lists (Aupplementary lists 1-5) must be provided. The previously developed programs are lined in gray, while 
the programs developed in the present work are in blue. In addition, the files to be provided by the user are 
shown in orange, the configuration files (Conf file) are in blue and the input/ output files are in black. 	
 
I) Scheme of the integrative workflow used to quantify modified peptides. Each arrow represents a step 
performed with the generic integration algorithm [ 27]. Standardized log2-ratio values at the PDM level zpq 
are obtained from the PDM-to-protein integration. The algorithm provides corrected PDM values by the 
corresponding protein value (xq_PDM), which are integrated to a category composed by a DM modifying a 
certain protein site (qdna), getting zq_pdm2qdna. Subsequently, xq_qdna is integrated to a category composed by all 
detected DM modifying a certain protein site (qna, zq_qdna2qna) or to ALL (zq_qdna2ALL). Finally, xq_qna is 






Figure 2.  DM0Solver, TrunkSolver and SiteSolver effectiveness. 
 
A) Representation of Comet-PTM experimental Δmass calculation. ∆mass = theoretical mass - 
experimental mass. In the first example the ∆mass is negative since the theoretical mass is greater than the 
experimental mass. In the second instance the ∆mass is positive, since the experimental mass is higher than 
the theoretical mass. 
 
B) Typical CometPTM Δmass histogram after executing FDRFilterer. The zoomed insets show some 
non-zero ∆mass corresponding to non modified peptides. 
 
C) XCorr distribution for targets (blue) and decoys (yellow).in the whole ∆mass range. The graph shows 
an Xcorr-bias towards far-negative Δmasses for targets and decoys. This representation was made after 
executing the PeakFDRer. 
 
D) Percentage of each label assignation by DM0Solver. Of the 36.47% of the total that DM0Solver 







C );2.97% NH₄⁺ adduct (ammonium adduct);1.60% Na adducts (sodium adducts); 1.19% H2O loss 
(water loss); 1.18% NH₄⁺ loss (ammonium adduct loss); 0.90% 3
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C. 
E) Percentage of each label assignation by TrunkSolver. Of the 12.31% of the total that TrunkSolver 
recovers, the following percentages per label were allocated:  45.06% tryptic cuts;32.99% +TMT(TMT 
gain);9.06%  Truncation(non-tryptic cut); 4.33% +TMT:Tryptic cut (TMT gain and a tryptic cut); 2.34% 
+TMT:Truncation (TMTgain and a non-tryptic cut);1.94% -TMT (TMT loss);1.68% -TMT: Trucation (TMT 
loss and non-tryptic cut); 1.57% +2TMT (double gain of TMT); 0.49% +TMT:Truncation (non-tryptic cut 
and double gain of TMT); 0.46% -2TMT:Tryptic cut (double loss of TMT with tryptic cut);0.06 % -
2TMT:Truncation (double loss of TMT and non-tryptic cut );0.01% -TMT:Tryptic cut (TMT loss and tryptic 
cut);0.01% -2TMT (double loss of TMT). 
F) Δmasses frequency variation before and after applying DM0Solver and TrunkSolver. The difference 
between the frequency of the Δmasses assigned by PeakAssignator after and before passing DM0Solver and 
TrunkSolver is shown. The Δmasses with the highest frequency differences are highlighted, such as:  
-357.259079Da (extra lysine plus TMT), -156.102444 Da (extra arginine), 0Da, 229.162932 (TMT). 
 
G) SiteSolver efficiency. The frequency of oxidation (15.993411 Da) distribution in the mouse ALBU 
peptide ADKTCFSTEP before and after passing SiteSolver is shown. The sequence contains only two 
allowed residues for this DM (C and F) in the user-curated list. Before SiteSolver the DM is distributed in 
two dispersed populations around C5 and F6, respectively. However, after passing SiteSolver with a working 
range of 3 in the parameter X, we managed to concentrate all the scans from this DM in this peptide on C5 
and F6, demonstrating the reassignment was correct. 	
 
H) Assignment correction percentage by SiteSolver for each position, setting the program parameter X 
equal to fourteen. The x axis represents the values of the X parameter and the y axes the percentage. One is 
the closest position to the original Δmass site and fourteen the furthest. The percentages are reflected: X = 
1:40.33%; X=2:16.75%; X=3:11.06%; X=4:6.67%; X=5:5.22%; X=6: 5.62%; X=7:4.60%; 
X=8:3.14%;X=9:3.30%,X=10:1.59%; X=11:0.59%; X=12: 0.40%; X=13:0.51%; X=14:0.22%. 
 
I) Assignment correction percentage by SiteSolver for each position, setting the program parameter X 
equal to six. The x axis represents the values of the X parameter and the y axes the percentage.   One is the 
closest position to the original Δmass site and six the furthest. The percentages are reflected for eah 
modification. Oxidation: X=1:51.16%; X=2:23.12%; X=3:9.54%, X=4:9.25%; X=5:3.18%; X=6:3.76%. 
Deamidation: X=1:41.07%; X=2:20.50%; X=3:13.9%; X=4:7.92%; X=5:7.66%; X=6:8.95%. 
Phosphorylation: X=1:36.96%; X=2:30.43%; X=3:18.48&; X=4:4.35%; X=5:2.17%; X=6:7.61%. 
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Figure 3. High-fat diet-associated PTM changes in plasma from LDLRKO mice. 
Nested pie charts show the pdms (with more than 5 quantified spectra) with statistically significant (n=5, 
ttest, FDR<=0.15) increases (A) and decreases (B). The graphs are proportional to the magnitude of the 
change between the control (LDLR KO CHOW) and the LDLR KO HFD samples, expressed in terms of -
log(p-value)*sign(zpdm2q_chow – zpdm2q_HFD). The adscription of the type of modification and the modified 
residue to the plasma proteins is depicted, and the magnitude of the pdms composing each one of these three 
graph layers was correspondingly summed. Ox, 2Ox, 3Ox and 4Ox: addition of one, two, three and four 
oxygens, respectively; Ca: replacement of 2 protons by calcium; HFK: hydroxykynurenine; NFK: dihydroxy-
N-fomaylkynurenine; KYN: Kynurenine; SULFI: cysteine sulfinic acid; SULFO: cysteine sulfonic acid; 
A>S: alanine by serine amino acid substitution; S>D: serine for aspartic acid substitution; A>S: alanine for 
serine substitution; OX_M->ASP: methionine oxidation to aspartic semialdehyde; OXOALA:  cysteine 
oxidation to oxoalanine; SULFONA: sulfonation; DEA: deamidation; M<D: methionine for aspartic acid 
substitution; N<S: asparagine for serine substitution; T<A: threonine alanine substitution; UK: unknown; 
ALBU: Serum albumin; APOA1: Apolipoprotein A-I; APOA2: Apolipoprotein A-II; APOB: Apolipoprotein 
B-100; APOC3: Apolipoprotein C3; APOE: Apolipoprotein E; HPT: Haptoglobin; D3Z5G7: Carboxylic 
ester hydrolase; A1AT2: Alpha-1-antitrypsin 1-2; A1AT3: Alpha-1-antitrypsin 1-3; A1AT5: Alpha-1-
antitrypsin 1-5; MUG1: Murinoglobulin-1; SPA3K (Serine protease inhibitor A3K);  A0A0R4J0I1: 
Serpina3k; TRFE: Serotransferrin; CO3: Complement component 3; HEMO: Hemopexin; FINC: 
Fibronectin; CERU: Ceruloplasmin; IGHM: Immunoglobulin heavy constant mu; CFAI: Complement factor 
I;  FIBA: Fibrinogen alpha chain; SPA3N: Serine protease inhibitor A3N; HBB1: Hemoglobin subunit beta-




Figure 4. High-fat diet-associated protein sites changes in plasma from LDL KO mice. 
 
Nested pie charts show the protein sites (qna) (with more than 4 quantified spectra) with statistically 
significant (n=5, ttest, FDR<=0.1) increases (A) and decreases (B). The graphs are proportional to the 
magnitude of the change between the control (LDLR KO CHOW) and the LDLR KO HFD samples, 
expressed in terms of -log(p-value)*sign(zq_qna2A_HFD – zq_qna2A_CHOW). The adscription of the protein modified 
site to the plasma proteins is depicted and the magnitude of the qnas composing each protein was 
correspondingly summed. For the 2-3 most relevant protein sites a heatmap of the standardized protein-
corrected protein_site_DM quantitation (zq_qdna2A) in each one of the samples according to the color scale is 
presented. The DMses modifying each protein site are depicted. Additionally, the magnitude of the change 
between the control (LDLR KO CHOW) and the LDLR KO HFD samples, expressed in terms of -log(p-
value)*sign(zq_qdna2A_HFD – zq_qdna2A_CHOW) (bars) and the number of spectra quantified (Number of scans) are 
shown. APOE: Apolipoprotein E; ALBU: Serum albumin; HPT: Haptoglobin; Q58EV2: Apoa1; FETUA: 
Alpha-2-HS-glycoprotein; A1AG1: Alpha-1-acid glycoprotein 1; APOA4: Apolipoprotein A-IV; SPA3K: 
Serine protease inhibitor A3K; A1AT2: Alpha-1-antitrypsin 1-2; SPA3K:Serine protease inhibitor A3;  PZP 
:Pregnancy zone; TRFE: Serotransferrin; APOB: Apolipoprotein B-100; A0A0R4J0I1: Serpina3k; APOE: 
Apolipoprotein E; MUG1: Murinoglobulin-1;  APOA1: Apolipoprotein A; A1AT5: Alpha-1-antitrypsin 1-5; 
HEMO: Hemopexin; CD5L: CD5 antigen-like; HBB1: Hemoglobin subunit beta-1; SPA3N: Serine protease 
inhibitor A3N; APOD: Apolipoprotein D; CFAH: Complement factor H; FETUA: Alpha-2-HS-glycoprotein; 
A1AG2: Alpha-1-acid glycoprotein; PROP: Properdin; CO3: Complement component 3; HPT: Haptoglobin; 
CES1F: Carboxylic ester hydrolase; A1AT3: Alpha-1-antitrypsin 1-3; GCAM: Ig gamma-2A chain C region; 
B1Q450: Hemoglobin beta chain subunit; HA10: H-2 class I histocompatibility antigen, Q10 alpha chain; 
APOA2: Apolipoprotein A-II; A0A087WR50: Fibronectin.    
 
 
Figure 5. Apolipoprotein E 3D structure. 
ApoE 3D structure taken from [55] P94 (circled in yellow), M118 (circled in red), M135 (circled in blue) are 





Figure 6. Albumin qnas and domains. 
Albumin sites (qna) (with more than 4 quantified spectra) with statistically significant (n=5, ttest, FDR<=0.1) 
increases (red) and decreases (blue). The bars are proportional to the magnitude of the change between the 
control (LDLR KO CHOW) and the LDLR KO HFD samples, expressed in terms of -log(p-
value)*sign(zq_qna2A_HFD – zq_qna2A_CHOW). Green squares represent domains, being D1 domain one, D2 domain 
two and D3 domain three. Pink boxes represent the subdomains A or B. Disulfide bridge is also represented 
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Supplementary configuration files tables: 
 




























































Supplementary Table 3. FDRFilterer configuration file. 
 
 
Supplementary Table 4. DM0Solver configuration file. 
 
scorecolumn xcorr      
mzcolumn exp_mz           
zcolumn charge            
seqcolumn plain_peptide            
seqdmcolumn delta_peptide    
proteincolumn protein   
decoyprefix DECOY         
score_min 3
ppm_max 31
calseqcolumn Cal_Sequence     
decimal_places 6


























































Supplementary Table 6.  PeakAssignator second execution configuration file. 
 
 


















































































































Supplementary Table 11.  Sticker configuration file using Unimod file (Supplementary List X) 
 
 









Supplementary List 1. Primary List for SiteSolver. 
DM Residue Freq 
-458.325864 NT 1 
-442.330949 K 1 
-442.330949 K 1 
-422.325864 NT 1 
-421.341848 K 1 
-406.330949 K 1 
-404.315299 K 1 
-403.331283 K 1 
-388.320384 K 1 
-376.312384 K 1 
-376.312384 K 1 
-360.330488 NT 1 
-360.330488 NT 1 
-359.333453 K 1 
-359.333453 NT 1 
-350.304734 K 1 
-344.276762 K 1 
-344.276762 NT 1 
-320.172118 K 1 

















-300.236431 C 1 
-286.220781 K 1 
-270.225867 K 1 
-260.205131 K 1 
-258.189481 K 1 
-256.210217 K 1 
-254.248711 K 1 
-246.189481 K 1 
-244.173831 NT 1 
-243.214968 K 1 
-242.230952 K 1 
-230.194566 K 1 
-230.194566 NT 1 
-229.162932 K 1 
-229.162932 NT 1 
-228.282014 K 1 
-228.282014 K 1 
-226.21741 NT 1 
-220.198983 K 1 
-217.162932 K 1 
-214.199652 NT 1 
-213.168017 K 1 
-210.222496 NT 1 
-203.18058 K 1 
-203.18058 NT 1 
-201.168017 K 1 
-201.168017 K 1 
-197.173102 NT 1 
-197.173102 NT 1 
-194.194566 K 1 
-187.185665 K 1 
-187.185665 NT 1 
-187.185665 K 1 
-187.152367 M 1 
-186.154031 K 1 
-186.154031 K 1 
-175.152367 NT 1 
-174.168351 K 1 
-172.138381 K 1 
-172.138381 K 1 
-171.178582 NT 1 
-170.159116 K 1 
48  
-170.159116 K 1 
-170.159116 M 1 
-167.147282 NT 1 
-159.157452 K 1 
-157.133802 K 1 
-157.133802 K 1 
-156.143466 NT 1 
-156.143466 K 1 
-156.143466 M 1 
-147.149452 NT 1 
-147.149452 NT 1 
-143.162537 K 1 
-143.126153 K 1 
-141.138887 K 1 
-141.138887 M 1 
-129.138887 NT 1 
-129.138887 K 1 
-121.141803 NT 1 
-115.120005 K 1 
-114.141007 K 1 
-114.141007 K 1 
-113.143972 NT 1 
-113.143972 K 1 
-112.138097 NT 1 
-103.009185 K 1 
-98.146092 C 1 
-98.146092 K 1 
-97.14905703 NT 1 
-97.14905703 K 1 
-95.14234703 NT 1 
-94.13899203 NT 1 
-91.009186 NT 1 
-90.025169 C 1 
-88.993535 C 1 
-82.151177 C 1 
-82.151177 K 1 
-75.014270 NT 1 
-72.998620 C 1 
-72.11742303 C 1 
-72.11742303 K 1 
-67.110108 NT 1 
-62.977885 K 1 
49  
-60.962235 C 1 
-59.037114 C 1 
-58.982970 C 1 
-56.12250803 C 1 
-56.12250803 K 1 
-46.946584 NT 1 
-45.987721 C 1 
-45.003705 C 1 
-33.987721 C 1 
-31.972071 C 1 
-31.935685 C 1 
-30.988055 C 1 
-28.990164 C 1 
-25.031634 C 1 
-22.971737 C 1 
-22.067486 C 1 
-12.995249 C 1 
-12.962235 C 1 
-11.033743 C 1 
-9.036719 C 1 
-3.929537 C 1 
-2.015650 C 1 
-1.031634 C 1 
-1.012295 NA 1 
-0.028279 NA 1 
3.032680 NA 1 
4.978931 C 1 
15.994915 W 1 
15.994915 A 1 
15.994915 F 1 
15.994915 M 1 
15.994915 C 1 
15.994915 P 1 
15.994915 W 1 
26.048664 Y 1 
31.989829 C 1 
31.989829 M 1 
31.989829 P 1 
31.989829 W 1 
31.989829 Y 1 
36.000000 F 1 
47.984745 K 1 
50  
47.984745 W 1 
49.955943 Y 1 
49.955943 Y 1 
54.010565 W 1 
57.024551 K 1 
57.024551 M 1 
57.024551 K 1 
57.024551 T 1 
57.024551 H 1 
62.01565 S 1 
61.982636 K 1 
71.032095 C 1 
71.032095 K 1 
72.02912997 NT 1 
72.02912997 M 1 
72.02912997 Y 1 
72.02912997 W 1 
73.016379 H 1 
73.019466 C 1 
89.014381 M 1 
91.975442 M 1 
100.024045 C 1 
100.024045 S 1 
152.980587 T 1 
154.065171 C 1 
168.080821 K 1 
182.096471 K 1 
197.227247 K 1 
209.018035 C 1 
230.146948 C 1 
230.146948 K 1 
244.173831 NT 1 
245.157847 Y 1 
245.157847 K 1 
246.189481 NT 1 
246.189481 K 1 
261.152762 NT 1 
261.152762 K 1 
261.152762 NT 1 
261.152762 K 1 
286.184396 NT 1 
286.184396 K 1 
51  
297.084987 NT 1 
297.084987 Y 1 
298.069003 Y 1 
458.325864 Y 1 
458.325864 T 1 
   




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary List 3. Artefact file for Sticker. 
d Cond_a Lab_ArtefactIdentifier Lab_Description Cond_m 
    NoArt     
-229.16358   (-TMT) No marcado   
-91.01015 C C_CM-IAM-NL Artefactos en Cys: C_DHA   
-320.172758 C C_CM-IAM-NL Artefactos en Cys: C_DHA-TMT   
0.98554 C C_CM-IAM-NL Artefactos en Cys: C_CM/DEA   
155.179435 C C_CM-IAM-NL Artefactos en Cys: C_UK   


































































































































































































































































































































































































































































































































1.986792 C C_CM-IAM-NL Artefactos en Cys: C_2DEA   
-148.032887 C C_CM-IAM-NL Artefactos en Cys: C_DHA+C_-
IAM 
  
-246.189985 Q Cyclation_Nterm-C-Q C y Q en N-term ciclados y no 
marcados 
1 
-246.189985 C Cyclation_Nterm-C-Q C y Q en N-term ciclados y no 
marcados 
1 
0.98554 Q DEA_2DEA Deamidaciones en general   
0.98554 N DEA_2DEA Deamidaciones en general   
1.986792 N DEA_2DEA Deamidaciones en general   
1.986792   QDEA_2DEA Deamidaciones en general   
-357.259079   DigPar (-K+TMT) Dihesti√≥n parcial   
15.993412 M M_ox,C_ox Oxidaci√≥n en M,Oxidaci√≥n 
en C 
  
15.993412 C M_ox,C_ox Oxidaci√≥n en M,Oxidaci√≥n 
en C 
  
16.980965 M M_OX+DEA En M : OX+DEA   
16.980965 N M_OX+DEA En  N: OX+DEA   
32.991275 M M_2OX+DEA/M_2OX+2DEA En M: 2OX+DEA   
32.991275 N M_2OX+DEA/M_2OX+2DEA En N: 2OX+DEA   
33.95246547 M M_2OX+DEA/M_2OX+2DEA En M : 2OX+2DEA   
33.95246547 N M_2OX+DEA/M_2OX+2DEA En N: 2OX+2DEA   
57.021005 M M_IAM_CM Artefactos por IAM y urea en 
M: M_IAM 
  
57.021005 H H_IAM_CM Artefactos por IAM y urea en 
H: H_IAM 
  
57.021005 K K_IAM_CM Artefactos por IAM y urea en 
K: K_IAM 
  
58.006072 M M_IAM_CM Artefactos por IAM y urea en 
M: M_CM 
  
58.006072 H H_IAM_CM Artefactos por IAM y urea en 
H: H_CM 
  
58.006072 K K_IAM_CM Artefactos por IAM y urea en 
K: K_CM 
  
100.015262 S T_100.01,S_100.01 Artefactos por hidorxilamina   
100.015262 T T_100.01,S_100.01 Artefactos por hidorxilamina   
229.162594   TMT Sobre-marcaje   
230.150072 SN TMT+DEA Sobre-marcaje+DEA (sin C)   
230.150072 T TMT+DEA Sobre-marcaje+DEA (sin C)   
230.150072 Y TMT+DEA Sobre-marcaje+DEA (sin C)   
230.150072 N TMT+DEA Sobre-marcaje+DEA (sin C)   
-228.177409   (-TMT+DEA) No marcado+DEA   
-129.14713 K TMT-fragments Artefactos asociados al TMT 
de masa te√≥rica desconocida. 
  
-129.14713   TMT-fragments Artefactos asociados al TMT 
de masa te√≥rica desconocida. 
1 
-114.137012 K TMT-fragments Artefactos asociados al TMT 
de masa te√≥rica desconocida. 
  
-114.137012   TMT-fragments Artefactos asociados al TMT 
de masa te√≥rica desconocida. 
1 
-147.157817 K TMT-fragments Artefactos asociados al TMT 
de masa te√≥rica desconocida. 
  
57  
-147.157817   TMT-fragments Artefactos asociados al TMT 
de masa te√≥rica desconocida. 
1 
-113.152907 K TMT-fragments Artefactos asociados al TMT 
de masa te√≥rica desconocida. 
  
-113.152907   TMT-fragments Artefactos asociados al TMT 
de masa te√≥rica desconocida. 
1 
-203.183662 K TMT-fragments Artefactos asociados al TMT 
de masa te√≥rica desconocida. 
  
-203.183662   TMT-fragments Artefactos asociados al TMT 
de masa te√≥rica desconocida. 
1 
-128.146038 K TMT-fragments Artefactos asociados al TMT 
de masa te√≥rica desconocida. 
  
-128.146038   TMT-fragments Artefactos asociados al TMT 
de masa te√≥rica desconocida. 
1 
-187.153235 K TMT-fragments Artefactos asociados al TMT 
de masa te√≥rica desconocida. 
  
-187.153235   TMT-fragments Artefactos asociados al TMT 
de masa te√≥rica desconocida. 
1 
-157.142248 K TMT-fragments Artefactos asociados al TMT 
de masa te√≥rica desconocida. 
  
-157.142248   TMT-fragments Artefactos asociados al TMT 
de masa te√≥rica desconocida. 
1 
-95.150944 K TMT-fragments Artefactos asociados al TMT 
de masa te√≥rica desconocida. 
  
-95.150944   TMT-fragments Artefactos asociados al TMT 
de masa te√≥rica desconocida. 
1 
-141.078696 K TMT-fragments Artefactos asociados al TMT 
de masa te√≥rica desconocida. 
  
-141.078696   TMT-fragments Artefactos asociados al TMT 
de masa te√≥rica desconocida. 
1 
-172.142429 K TMT-fragments Artefactos asociados al TMT 
de masa te√≥rica desconocida. 
  
-172.142429   TMT-fragments Artefactos asociados al TMT 
de masa te√≥rica desconocida. 
1 
-186.157635 K TMT-fragments Artefactos asociados al TMT 
de masa te√≥rica desconocida. 
  
-186.157635   TMT-fragments Artefactos asociados al TMT 
de masa te√≥rica desconocida. 
1 
-171.159939 K TMT-fragments Artefactos asociados al TMT 
de masa te√≥rica desconocida. 
  
-171.159939   TMT-fragments Artefactos asociados al TMT 




Supplementary List 4. Unimod file for Sticker. 
d Lab_Unimod_Label Lab_Unimod_Description 
  NoLab   
495.19519 HexNAc1dHex2 HexNAc1dHex2 
494.174789 HexNAc(1)NeuAc(1) HexNAc NeuAc 
486.158471 Hex3 Hex3 
486.11556 HexNAc(2)Sulf(1) HexNAc(2) Sulf 
484.228162 EQIGG Sumo mutant Smt3-WT tail following 
trypsin digestion 
470.266839 Withaferin Modification of cystein by withaferin 
470.163556 dHex(1)Hex(2) Hex2dHex1 
469.716159 triiodo triiodo 
58  
469.228496 NQIGG SUMOylation by Giardia lamblia 
469.143155 Hex(1)NeuGc(1) Hex NeuGc 
456.104615 FMN3 S-(4a-FMN) 
456.069261 EGCG1 (-)-epigallocatechin-3-gallate 
454.210387 betaFNA beta-Funaltrexamine 
454.088965 FMN flavin mononucleotide 
453.212452 Puromycin Puromycin 
453.14824 Hex(1)NeuAc(1) Hex NeuAc ---OR--- HexNAc Kdn 
452.034807 IASD Iodoacetamide derivative of stilbene 
(reaction product with thiol) 
445.098527 Hex(1)HexNAc(1)Phos(1) Hex HexNAc Phos 
445.089011 Hex(1)HexNAc(1)Sulf(1) Hex HexNAc Sulf 
440.152991 Hex(1)Pent(2)Me(1) Hex:1 Pent:2 Me:1 
438.094051 FMN2 O3-(riboflavin phosphoryl) 
437.201774 bisANS-sulfonates BisANS with loss of both sulfonates 
426.137341 Hex(1)Pent(2) Hex Pent(2) 
420.051719 Unknown:420 Unidentified modification of 420.0506 
found in open search 
418.137616 dipyrrole dipyrrolylmethanemethyl 
411.259403 LRGG+dimethyl LeudimethylArgGlyGly 
406.158745 HexNAc2 HexNAc2 
404.071978 PhosphoHex(2) H1O3P1Hex2 
404.062462 Hex(2)Sulf(1) Hex(2) O(3) S 
397.243753 LRGG+methyl LeumethylArgGlyGly 
387.127779 -Glu-Glu-Glu- triglutamyl 
386.110369 C-Asn-deriv (3-aminopropyl)(L-aspartyl-1-
amino)phosphoryl-5-adenosine 
383.228103 LeuArgGlyGly Ubiquitination 
380.147118 cytopiloyne+H2O nucleophilic addition to 
cytopiloyne+H2O 
377.689944 tri-Iodination tri-Iodination 
372.142033 4AcAllylGal 2,3,4,6-tetra-O-Acetyl-1-allyl-alpha-D-
galactopyranoside modification of 
cysteine 
368.344302 C-cholesterol cholesterol ester 
365.132196 Hex(1)HexNAc(1) Hex1HexNAc1 
364.076278 Dap-DSP Diaminopimelic acid-DSP monolinked 
362.136553 cytopiloyne nucleophilic addtion to cytopiloyne 
349.137281 HexNAc1dHex1 HexNAc1dHex1 
348.193674 LG-Hlactam-K Levuglandinyl - lysine hydroxylactam 
adduct 
345.047435 p-guanosine phospho-guanosine 
343.149184 QTGG SUMOylation leaving GlnThrGlyGly 
343.031785 cGMP S-guanylation Fe-cluster hydrogenase 
diiron subcluster 
340.167459 BADGE Bisphenol A diglycidyl ether derivative 
340.100562 glucosylgalactosyl glucosylgalactosyl hydroxylysine 
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340.085794 p-pantetheine Phosphopantetheine 
338.084912 Hex(1)HexA(1) Hex HexA 
335.121631 Pent(1)HexNAc(1) Pent HexNAc 
332.19876 LG-lactam-K Levuglandinyl - lysine lactam adduct 
332.19876 Andro-H2O andrographolide with the loss of H2O 
330.136176 CIGG Ubiquitin D (FAT10) leaving after 
chymotrypsin digestion Cys-Ile-Gly-Gly 
329.05252 p-adenosine AMP 
327.240959 NA-OA-NO2 Nitroalkylation by Nitro Oleic Acid 
325.225309 NA-LNO2 Nitroalkylation by Nitro Linoleic Acid 
324.105647 Gal-Glu Lactosylation 
324.035867 RNPXL Simulate peptide-RNA conjugates 
322.020217 IodoU-AMP (Iodo)-uracil MP 
320.100836 ZQG carbobenzoxy-L-glutaminyl-glycine 
316.203845 LG-pyrrole Levuglandinyl-lysine pyrrole adduct 
316.138088 IBTP Thio Ether Formation - BTP Adduct 
314.188195 LG-anhydrolactam Levuglandinyl-lysine anhydrolactam 
adduct 
310.047738 AFB1_Dialdehyde adduction of aflatoxin B1 Dialdehyde 
to lysine 
309.205242 Ahx2+Hsl C-terminal homoserine lactone and 
two aminohexanoic acids 
308.148455 UgiJoullieProGlyProGly Side reaction of PGPG with Side chain 
of aspartic or glutamic acid 
308.110732 dHex(1)Hex(1) Hex1dHex1 
307.090331 NeuGc N-glycoyl neuraminic acid 
306.171876 LG-Hlactam-R Levuglandinyl - arginine hydroxylactam 
adduct 
306.095082 Unknown:306 Unidentified modification of 306.0952 
found in open search 
306.025302 p-uridine uridine phosphodiester 
305.068156 Glutathione glutathione disulfide 
305.041287 PhosphoCytidine Cytidine monophosphate 
301.986514 Unknown:302 Unidentified modification of 301.9864 
found in open search 




294.095082 Hex(1)Pent(1) Hex Pent 
291.095417 NeuAc N-acetyl neuraminic acid 
290.176961 LG-lactam-R Levuglandinyl - arginine lactam adduct 
287.055563 EGCG2 (-)-dehydroepigallocatechin 
283.045704 p-GlcNAc N-acetylglucosamine-1-phosphoryl 
283.036187 s-GlcNAc O3S1HexNAc1 
282.052824 Arg2HPG bis(hydroxphenylglyoxal) arginine 
276.055146 CresylSaligeninPhosphate Cresyl-Saligenin-phosphorylation 
275.100502 MurNAc N-Acetylmuramic acid 
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272.250401 Geranyl-geranyl Geranyl-geranyl 
268.039202 NO_SMX_SMCT Nitroso Sulfamethoxazole 
semimercaptal thiol adduct 
267.158292 DimethylamineGMBS Modified GMBS X linker 
267.031377 NO_SMX_SIMD Nitroso Sulfamethoxazole Sulfinamide 
thiol adduct 
266.203451 retinal retinal 
266.13068 EHD-diphenylpentanone 2-ethyl-3-hydroxy-1,3-diphenylpentan-
1-one 
266.057909 Arg2PG Adduct of phenylglyoxal with Arg 
265.146664 MM-diphenylpentanone 3-methyl-5-(methylamino)-1,3-
diphenylpentan-1-one 
264.187801 didehydroretinyl 3,4-didehydroretinylidene 
264.084518 Pent(2) Pent(2) 
263.237491 Tween80 Tween 80 synthetic polymer terminus 
263.131014 BMP-piperidinol 1-methyl-3-benzoyl-4-hydroxy-4-
phenylpiperidine 
258.085186 -Glu-Glu- diglutamyl 
258.014069 Phosphogluconoylation Phosphogluconoylation 
252.044287 NO_SMX_SEMD Nitroso Sulfamethoxazole 
Sulphenamide thiol adduct 
251.793296 di-Iodination di-Iodination 
249.981018 Unknown:250 Unidentified modification of 249.981 
found in open search 
248.19876 Unknown:248 Unidentified modification of 248.1986 
found in open search 
243.085521 pupylation addition of GGE 
242.101505 GGQ SUMOylation leaving GlyGlyGln 
242.019154 p-Man phosphoglycosyl-D-mannose-1-
phosphoryl 
240.11503 lapachenole lapachenole photochemically added to 
cysteine 
238.229666 Palmitoylation Palmitoylation 
236.214016 palmitoleyl palmitoleyl 
234.16198 BHTOH Michael addition of t-butyl 
hydroxylated BHT (BHTOH) to C, H or K 
234.073953 Unknown:234 Unidentified modification of 234.0742 






231.02966 PyridoxalPhosphateH2 PLP bound to lysine reduced by sodium 
borohydride (NaBH4) to create amine 
linkage 
229.162932 TMT6plex Sixplex Tandem Mass Tag 
229.014009 Pyridoxal-phos Pyridoxal phosphate 
228.111007 Bacillosamine 2,4-diacetamido-2,4,6-
trideoxyglucopyranose 
225.090212 Dipyridyl Cys modified with dipy ligand 
220.182715 hydroxyfarnesyl hydroxyfarnesyl 
220.058303 Kdo Glycosylation with KDO 
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218.167065 BHT Michael addition of BHT quinone 
methide to Cysteine and Lysine 
216.099774 Unknown:216 Unidentified modification of 216.1002 
found in open search 
214.971084 SPITC 4-sulfophenyl isothiocyanate 
212.00859 phosphoRibosyl phosphate-ribosylation 
210.986535 TNBS tri nitro benzene 
210.198366 Myristoylation Myristoylation 
210.16198 Unknown:210 Unidentified modification of 210.1616 
found in open search 
210.00205 CarboxymethylDTT Carboxymethylated DTT modification 
of cysteine 
209.018035 CarbamidomethylDTT Carbamidomethylated DTT 
modification of cysteine 
208.182715 myristoleylation (cis-delta 5)-tetradecaenoyl 
206.167065 myristoyl-4H (cis,cis-delta 5, delta 8)-
tetradecadienoyl 
204.187801 Farnesylation Farnesylation 
203.950987 Haloxon O-Dichloroethylphosphate 
203.079373 HexNAc N-Acetylhexosamine 
201.970617 Hg Mercury Mercaptan 
198.981352 DNPS 2,4-Dinitrobenzenesulfenyl 
197.04531 glycerylPE glycerylphosphorylethanolamine 
192.063388 Hep Heptose 
190.074228 Bromobimane Monobromobimane derivative 
189.188947 EQATd5 EAPTA d5 
188.156501 Triton Triton synthetic polymer terminus 
188.032956 Lipoyl Lipoyl 
185.189198 spermine spermine adduct 
184.157563 EQAT EAPTA d0 
184.07961 MTSL Cys modification by (1-oxyl-2,2,5,5-
tetramethyl-3-pyrroline-3-
methyl)methanesulfonate (MTSL) 
183.983029 3sulfo derivatization by N-term modification 
using 3-Sulfobenzoic succinimidyl ester 
183.035399 AEBS Aminoethylbenzenesulfonylation 
178.047738 Galactosyl Gluconoylation 
176.744957 Unknown:177 Unidentified modification of 176.7462 
found in open search 
176.032088 N-glucuronyl hexuronic acid 
175.042199 NDA naphthalene-2,3-dicarboxaldehyde 
175.030314 NEMsulfurWater N-ethylmaleimideSulfurWater 
174.025169 Thiadiazole Thiadiazolydation of Cys 
173.092617 Ub-VME Ubiquitin vinylmethylester 
172.992127 Cys->SecNEM N-ethylmaleimide on selenocysteines 
172.05243 Menadione-HQ Menadione hydroquinone derivative 
170.036779 Menadione-Q Menadione quinone derivative 
170.013281 Cresylphosphate o-toluyl-phosphorylation 
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169.048741 His+O(2) Photo-induced histidine adduct 
168.0245 phenylsulfonylethyl reaction with phenyl vinyl sulfone 
167.982375 3-phosphoglyceryl 3-phosphoglyceryl 
166.001457 DNCB_hapten Chemical reaction with 2,4-dinitro-1-
chloro benzene (DNCB) 
165.164326 Tween20 Tween 20 synthetic polymer terminus 
164.060231 O-Diisopropylphosphate O-Diisopropylphosphorylation 
163.04557 PEITC Phenethyl isothiocyanate 
162.125595 Unknown:162 Unidentified modification of 162.1258 
found in open search 
162.080967 O-pinacolylmethylphosphonate O-pinacolylmethylphosphonylation 
162.052824 Hex Hexose 
161.068808 HexN Hexosamine 
160.037173 glucosone Condensation product of glucosone 
159.932662 pyrophospho pyrophosphorylation of Ser/Thr 
159.068414 serotonylation 5-glutamyl serotonin 
159.035399 #¿NOMBRE? Addition of N-formyl met 
159.035399 thioacylPA membrane protein extraction 
158.13068 redHNE reduced 4-Hydroxynonenal 
157.019749 NEMsulfur N-ethylmaleimideSulfur 
156.11503 HNE 4-hydroxynonenal (HNE) 
156.101111 Arg Addition of arginine due to 
transpeptidation 
155.821022 Dibromo Dibromo 
154.135765 decanoyl lipid 
154.09938 4-ONE 4-Oxononenal (ONE) 
154.074228 UgiJoullieProGly Side reaction of PG with Side chain of 
aspartic or glutamic acid 
154.026609 Delta:H(6)C(7)O(4) methylglyoxal-derived 
tetrahydropyrimidine 
154.00311 glycerophospho glycerophospho 
152.006087 Diethylphosphothione O-diethylphosphothione 
151.996571 DTT DTT adduct of cysteine 
150.041585 cGMP+RMP-loss S-guanylation-2 
149.02992 BITC Benzyl isothiocyanate 
148.037173 glycosyl glycosyl-L-hydroxyproline 
146.057909 Fuc Fucose 
146.036779 hydroxycinnamyl hydroxycinnamyl 
145.019749 CAMthiopropanoyl 3-(carbamidomethylthio)propanoyl 
144.042259 3-deoxyglucosone Condensation product of 3-
deoxyglucosone 
144.042259 2-dimethylsuccinyl S-(2-dimethylsuccinyl) cysteine 
143.058243 NEMhyd Nethylmaleimidehydrolysis 
142.110613 Diphthamide Diphthamide 
141.042593 Oxidation+NEM N-ethylmaleimide on cysteine sulfenic 
acid 
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138.104465 HNE-Delta:H(2)O Dehydrated 4-hydroxynonenal 
137.16403 TMAB-d9 d9-4-trimethyllammoniumbutyryl- 
136.088815 4-ONE+Delta:H(-2)O(-1) Dehydrated 4-Oxononenal Michael 
adduct 
136.028931 Diethylphosphate O-Diethylphosphorylation 
136.001656 BEMAD_ST Beta elimination of modified S or T 
followed by Michael addition of DTT 
135.983029 CAF sulfonation of N-terminus 
135.044916 O-Et-N-diMePhospho O-ethyl, N-dimethyl phosphate 
135.032028 2-nitrobenzyl Tyrosine caged with 2-nitrobenzyl 
(ONB) 
134.048013 PyMIC 3-methyl-2-pyridyl isocyanate 
133.052764 Iodoacetanilide iodoacetanilide derivative 
133.019749 HCysteinyl S-homocysteinylation 
132.068748 benzylguanidine modification of the lysine side chain 
from NH2 to guanidine with a H 
removed in favor of a benzyl group 
132.057515 Propiophenone Propiophenone 
132.042259 Pentose Pentose 
132.021129 Arg1HPG Hydroxyphenylglyoxal arginine 
132.021129 Difuran Chemical modification of the 
diiodinated sites of thyroglobulin by 
Suzuki reaction 
130.026609 2-monomethylsuccinyl S-(2-monomethylsuccinyl) cysteine 
129.057849 Gly->Trp Gly->Trp substitution 
129.042593 -Glu- monoglutamyl 
129.042593 NMMhyd Nmethylmaleimidehydrolysis 
128.131349 spermidine spermidine adduct 
128.107539 TMAB-d0 4-trimethyllammoniumbutyryl- 
128.094963 Lys Addition of lysine due to 
transpeptidation 
127.063329 SMA N-Succinimidyl-2-morpholine acetate 
126.104465 octanoyl octanoyl 
125.896648 Iodination Iodination 
125.047679 NEM N-ethylmaleimide on cysteines 
123.974787 Dimethylphosphothione O-dimethylphosphothione 
123.00853 GPI-anchor glycosylphosphatidylinositol 
122.073165 Delta:H(10)C(8)O(1) crotonaldehyde-derived dimethyl-FDP-
lysine 
122.036779 Carboxyethylpyrrole Carboxyethylpyrrole 
122.013281 O-Isopropylphosphate O-Isopropylphosphorylation 
121.035005 PET phosphorylation to pyridyl thiol 
120.034017 O-Isopropylmethylphosphonate O-Isopropylmethylphosphonylation 
120.0245 BEMAD_C Beta elimination of alkylated Cys 
followed by Michael addition of DTT 
120.0245 ethylsulfonylethyl reaction with ethyl vinyl sulfone 
120.021129 PS_Hapten reaction with phenyl salicylate (PS) 
119.037114 pyridylacetyl pyridylacetyl 
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119.037114 PIC phenyl isocyanate 
119.004099 Cysteinyl Cysteinylation 
118.065674 DHP Dehydropyrrolizidine alkaloid 
(dehydroretronecine) on cysteines 
117.024835 HCysThiolactone N-Homocysteine thiolactone 
116.997965 Phosphopropargyl phospho-propargylamine 
116.010959 2-succinyl S-(2-succinyl) cysteine 
115.042199 Ala->Trp Ala->Trp substitution 
114.042927 GlyGly ubiquitinylation residue 
114.042927 Dicarbamidomethyl Double Carbamidomethylation 
114.031694 Gluratylation Glutarylation 
113.084064 Acetylhypusine Acetylhypusine 
112.05243 Acrolein112 Acrolein addition +112 
111.068414 DMPO DMPO spin-trap nitrone adduct 
111.032028 NMM Nmethylmaleimide 
109.959137 monomethylphosphothione O-methylphosphothione 
109.052764 me-pyrroline 4-methyl-delta-1-pyrroline-5-carboxyl 
109.048119 dNIC deuterated Nicotinic Acid 
108.975121 Methamidophos-S S-methyl amino phosphinate 
108.021129 HydroxymethylOP 2-ammonio-6-[4-(hydroxymethyl)-3-
oxidopyridinium-1-yl]- hexanoate 
107.997631 O-Dimethylphosphate O-Dimethylphosphorylation 
107.997631 Ethylphosphate O-Ethylphosphorylation 
107.979873 MeMePhosphorothioate S-Methyl Methyl phosphorothioate 
107.077339 AHA-Alkyne Azidohomoalanine (AHA) bound to 
propargylglycine-NH2 (alkyne) 
107.013615 N-dimethylphosphate N-dimethylphosphate 
106.041865 Gly->Tyr Gly->Tyr substitution 
106.041865 Saligenin o-toluene 
106.00885 methylsulfonylethyl reaction with methyl vinyl sulfone 
105.897267 Cation:Ag Replacement of proton by silver 
105.057849 S-pyridylethyl S-pyridylethylation 
105.021464 NIC Nicotinic Acid 
104.965913 Cys->CamSec Sec Iodoacetamide derivative 
104.071154 Tris tris adduct causes 104 Da addition at 
asparagine-succinimide intermediate 
103.960719 DimethylArsino Reaction with dimethylarsinous (AsIII) 
acid 
101.084064 HN2_mustard Modification by hydroxylated 
mechloroethamine (HN-2) 
100.016044 Methylmalonylation Methylmalonylation on Serine 
99.079647 Gly->Arg Gly->Arg substitution 
99.068414 NIPCAM N-isopropylcarboxamidomethyl 
99.047285 Ser->Trp Ser->Trp substitution 
98.073165 MesitylOxide Acetone chemical artifact 
97.089149 Acetyldeoxyhypusine Acetyldeoxyhypusine 
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97.016378 maleimide maleimide 
96.057515 Delta:H(8)C(6)O(1) Reduced acrolein addition +96 
95.943487 Thio-phospho Thiophosphorylation 
94.967714 sulfo+amino aminotyrosine with sulfation 
94.041865 Acrolein94 Acrolein addition +94 
93.981981 O-Methylphosphate O-Methylphosphorylation 
92.997965 Methamidophos-O O-methyl amino phosphinate 
92.026215 Ala->Tyr Ala->Tyr substitution 
90.04695 Gly->Phe Gly->Phe substitution 
89.026549 Pro->Trp Pro->Trp substitution 
87.068414 hypusine hypusine 
87.050655 ser_thr_DAET phosphorylation to amine thiol 
87.032028 glycidamide glycidamide adduct 
87.010899 Val->Trp Val->Trp substitution 
86.036779 HMVK86 Michael addition of 
hydroxymethylvinyl ketone to cysteine 
86.036779 GEE transamidation of glycine ethyl ester to 
glutamine 
86.036779 hydroxyisobutyryl 2-hydroxyisobutyrylation 
86.000394 Malonyl Malonylation 
85.063997 Ala->Arg Ala->Arg substitution 
85.052764 NEIAA-d0 N-ethyl iodoacetamide-d0 
85.031634 Thr->Trp Thr->Trp substitution 
83.070128 Cys->Trp Cys->Trp substitution 
80.985078 Arg->Npo Arginine replacement by 
Nitropyrimidyl ornithine 
80.037448 Gly->His Gly->His substitution 
80.026215 Delta:H(4)C(5)O(1) methylglyoxal-derived argpyrimidine 
79.966331 Phospho Phosphorylation 
79.956815 Sulfation O-Sulfonation 
79.91652 selenyl selenyl 
78.04695 pyrrole 2,5-dimethypyrrole 
77.987066 Methylphosphonate Methylphosphonylation 
77.910511 bromo bromination 
76.0313 Acrolein76 Acrolein addition +76 
76.0313 Ser->Tyr Ser->Tyr substitution 
76.0313 Ala->Phe Ala->Phe substitution 
75.998285 DeStreak Cysteine mercaptoethanol 
75.980527 EDT EDT 
74.019021 Gly->Met Gly->Met substitution 
72.995249 Xle->Trp Leu/Ile->Trp substitution 
72.036386 Asn->Trp Asn->Trp substitution 
72.021129 carboxyethyl carboxyethyl 
72.021129 Gly->Glu Gly->Glu substitution 
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72.021129 Dihydroxyimidazolidine Dihydroxy methylglyoxal adduct 
72.021129 Ethoxyformyl Ethoxyformylation 
71.073499 Deoxyhypusine Deoxyhypusine 
71.073499 Gly->Lys Gly->Lys substitution 
71.073499 Dimethylaminoethyl Cys alkylation by dimethylaminoethyl 
halide 
71.05237 Asp->Trp Asp->Trp substitution 
71.037114 Propionamide Acrylamide adduct 
71.037114 Gly->Gln Gly->Gln substitution 
71.013304 Delta:H(3)C(3)O(2) methylglyoxal-derived 
carboxyethyllysine 
70.041865 Croton Crotonaldehyde 
70.041865 Butyryl Butyryl 
70.005479 pyruv-iminyl N-pyruvic acid 2-iminyl 
69.069083 Ser->Arg Ser->Arg substitution 
68.0626 Piperidination Piperidination 
68.026215 Crotonyl Crotonylation 
67.922055 dichlorination Dichlorination 
66.021798 Ala->His Ala->His substitution 
66.010565 Pro->Tyr Pro->Tyr substitution 
66.010565 Furan Chemical modification of the iodinated 
sites of thyroglobulin by Suzuki 
reaction 
63.994915 Val->Tyr Val->Tyr substitution 
63.979659 Delta:O(4) Tryptophan oxidation to dihydroxy-N-
formaylkynurenine 
63.9619 SulfurDioxide SulfurDioxide 
62.01565 MDA62 MDA adduct +62 
62.01565 Thr->Tyr Thr->Tyr substitution 
61.921774 Cation:Cu Replacement of proton by copper 
61.913495 Cation:Zn[II] Replacement of 2 protons by zinc 
60.054144 Cys->Tyr Cys->Tyr substitution 
60.036386 Ser->Phe Ser->Phe substitution 
60.003371 MercaptoEthanol 2-OH-ethyl thio-Ser 
60.003371 Ala->Met Ala->Met substitution 
59.04969 trimethyl-OH 5-hydroxy-N6,N6,N6-trimethyl 
59.048347 Pro->Arg Pro->Arg substitution 
59.019355 AEC-MAEC aminoethylcysteine 
58.041865 Delta:H(6)C(3)O(1) Reduced acrolein addition +58 
58.029289 Carbofuran 2,3-dihydro-2,2-dimethyl-7-
benzofuranol N-methyl carbamate 
58.020735 Gln->Trp Gln->Trp substitution 
58.005479 Carboxymethyl Iodoacetic acid derivative 
58.005479 Ala->Glu Ala->Glu substitution 
58.005479 Gly->Asp Gly->Asp substitution 
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57.98435 Lys->Trp Lys->Trp substitution 
57.057849 Ala->Lys Ala->Lys substitution 
57.03672 Glu->Trp Glu->Trp substitution 
57.032697 Val->Arg Val->Arg substitution 
57.021464 Carbamidomethyl Iodoacetamide derivative 
57.021464 Ala->Gln Ala->Gln substitution 
57.021464 Gly->Asn Gly->Asn substitution 
57.021464 Gly Addition of Glycine 
56.0626 Diethylation Diethylation, analogous to 
Dimethylation 
56.0626 Gly->Xle Gly->Leu/Ile substitution 
56.026215 Acrolein56 Acrolein addition +56 
55.919696 Cation:Ni[II] Replacement of 2 protons by nickel 
55.053433 Thr->Arg Thr->Arg substitution 
55.038828 Met->Trp Met->Trp substitution 
54.010565 MDA54 MDA adduct +54 
54.010565 MG-H1 Methylglyoxal-derived 
hydroimidazolone 
53.971735 trifluoro trifluoroleucine replacement of leucine 
53.919289 Cation:Fe[II] Replacement of 2 protons by iron 
53.091927 Cys->Arg Cys->Arg substitution 
52.911464 Cation:Fe[III] Replacement of 3 protons by iron 
50.026883 Ser->His Ser->His substitution 
50.01565 Pro->Phe Pro->Phe substitution 
49.979265 Xle->Tyr Leu/Ile->Tyr substitution 
49.020401 Asn->Tyr Asn->Tyr substitution 
49.020401 His->Trp His->Trp substitution 
48.036386 Asp->Tyr Asp->Tyr substitution 
48 Val->Phe Val->Phe substitution 
47.984744 Cysteic_acid cysteine oxidation to cysteic acid 
47.944449 SeMet Selenium replaces sulfur 
46.020735 Thr->Phe Thr->Phe substitution 
45.987721 b-methylthiol Beta-methylthiolation 
45.987721 Gly->Cys Gly->Cys substitution 
44.985078 Nitro Oxidation to nitro 
44.059229 Cys->Phe Cys->Phe substitution 
44.026215 EtOH Ethanolation 
44.026215 Gly->Thr Gly->Thr substitution 
44.008456 S-Eth S-Ethylcystine from Serine 
44.008456 Ser->Met Ser->Met substitution 
43.989829 carboxyl Carboxylation 
43.989829 Ala->Asp Ala->Asp substitution 
43.953444 Delta:H(-4)O(3) Tryptophan oxidation to hydroxy-bis-
tryptophandione 
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43.042199 Ethanolamine Carboxyl modification with 
ethanolamine 
43.017047 Xle->Arg Leu/Ile->Arg substitution 
43.005814 Carbamyl Carbamylation 
43.005814 Ala->Asn Ala->Asn substitution 
42.058184 Asn->Arg Asn->Arg substitution 
42.04695 tri-Methylation tri-Methylation 
42.04695 Gly->Val Gly->Val substitution 
42.04695 Ala->Xle Ala->Leu/Ile substitution 
42.04695 Propyl Propyl 
42.021798 Guanidination Guanidination 
42.021798 amidino amidino 
42.010565 Acetyl Acetylation 
42.010565 Ser->Glu Ser->Glu substitution 
41.074168 Asp->Arg Asp->Arg substitution 
41.062935 Ser->Lys Ser->Lys substitution 
41.026549 amidine amidination of lysines or N-terminal 
amines with methyl acetimidate 
41.026549 Ser->Gln Ser->Gln substitution 
41.001397 AzidoF Azidophenylalanine 
40.0313 Propionald+40 Propionaldehyde +40 
40.0313 Gly->Pro Gly->Pro substitution 
40.006148 Pro->His Pro->His substitution 
39.994915 Pyro-cmC S-carbamoylmethylcysteine cyclization 
(N-terminus) 
39.994915 G-H1 Glyoxal-derived hydroimiadazolone 
39.010899 Phe->Trp Phe->Trp substitution 
38.01565 Acrolein38 Acrolein addition +38 
37.990498 Val->His Val->His substitution 
37.955882 Cation:K Replacement of proton by potassium 
37.946941 Cation:Ca[II] Replacement of 2 protons by calcium 
37.031634 Propargylamine propargylamine 
36.011233 Thr->His Thr->His substitution 
35.004751 Gln->Tyr Gln->Tyr substitution 
34.968366 Lys->Tyr Lys->Tyr substitution 
34.049727 Cys->His Cys->His substitution 
34.020735 Glu->Tyr Glu->Tyr substitution 
33.987721 Pro->Met Pro->Met substitution 
33.98435 Xle->Phe Leu/Ile->Phe substitution 
33.969094 Homocysteic_acid methionine oxidation to homocysteic 
acid 
33.961028 Chlorination Chlorination of tyrosine residues 
33.951335 Leu->MetOx Leu->Met substitution and 
sulfoxidation 
33.025486 Asn->Phe Asn->Phe substitution 
69  
32.056407 CHD2 DiMethyl-CHD2 
32.041471 Asp->Phe Asp->Phe substitution 
32.022844 Met->Tyr Met->Tyr substitution 
31.989829 dihydroxy dihydroxy 
31.989829 Pro->Glu Pro->Glu substitution 
31.972071 persulfide persulfide 
31.972071 Val->Met Val->Met substitution 
31.972071 Ala->Cys Ala->Cys substitution 
31.935685 Lys->CamCys Lys->Cys substitution and 
carbamidomethylation 
31.042199 Pro->Lys Pro->Lys substitution 
31.005814 Pro->Gln Pro->Gln substitution 
30.010565 hydroxymethyl hydroxymethyl 
30.010565 Ala->Thr Ala->Thr substitution 
30.010565 Gly->Ser Gly->Ser substitution 
30.010565 methylol formaldehyde induced modifications 
29.992806 Thr->Met Thr->Met substitution 
29.978202 Arg->Trp Arg->Trp substitution 
29.974179 quinone quinone 
29.974179 Val->Glu Val->Glu substitution 
29.039125 Delta:H(5)C(2) Dimethylation of proline residue 
29.026549 Val->Lys Val->Lys substitution 
29.015316 Ethyl+Deamidated deamidation followed by esterification 
with ethanol 
28.990164 SNO nitrosylation 
28.990164 Val->Gln Val->Gln substitution 
28.042534 Gln->Arg Gln->Arg substitution 
28.0313 di-Methylation di-Methylation 
28.0313 Acetald+28 Acetaldehyde +28 
28.0313 Ethyl Ethylation 
28.0313 Ala->Val Ala->Val substitution 
28.0313 Cys->Met Cys->Met substitution 
28.006148 Lys->Arg Lys->Arg substitution 
27.994915 Formyl Formylation 
27.994915 Ser->Asp Ser->Asp substitution 
27.994915 Thr->Glu Thr->Glu substitution 
27.958529 Delta:H(-4)O(2) Tryptophan oxidation to beta-
unsaturated-2,4-bis-tryptophandione 
27.058518 Glu->Arg Glu->Arg substitution 
27.047285 Thr->Lys Thr->Lys substitution 
27.047285 ethylamino ethyl amino 
27.010899 Ser->Asn Ser->Asn substitution 
27.010899 Thr->Gln Thr->Gln substitution 
26.052036 Ser->Xle Ser->Leu/Ile substitution 
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26.033409 Cys->Glu Cys->Glu substitution 
26.01565 Acetald+26 Acetaldehyde +26 
26.01565 Ala->Pro Ala->Pro substitution 
26.004417 His->Tyr His->Tyr substitution 
25.085779 Cys->Lys Cys->Lys substitution 
25.060626 Met->Arg Met->Arg substitution 
25.049393 Cys->Gln Cys->Gln substitution 
24.995249 cyano cyano 
23.974848 Xle->His Leu/Ile->His substitution 
23.958063 Cation:Al[III] Replacement of 3 protons by 
aluminium 
23.015984 Asn->His Asn->His substitution 
23.015984 Tyr->Trp Tyr->Trp substitution 
22.031969 Asp->His Asp->His substitution 
21.98435 glyoxalAGE glyoxal-derived AGE 
21.981943 Sodiated Sodium adduct 
21.969392 Cation:Mg[II] Replacement of 2 protons by 
magnesium 
19.989829 hydroxykynurenin tryptophan oxidation to 
hydroxykynurenin 
19.042199 His->Arg His->Arg substitution 
19.009836 Gln->Phe Gln->Phe substitution 
18.973451 Lys->Phe Lys->Phe substitution 
18.940436 Lys->MetOx Lys->Met substitution and 
sulfoxidation 
18.025821 Glu->Phe Glu->Phe substitution 
18.010565 Pro->HAVA Proline oxidation to 5-hydroxy-2-
aminovaleric acid 
17.990578 Fphe fluorination 
17.974179 Pro->Asp Pro->Asp substitution 
17.956421 Xle->Met Leu/Ile->Met substitution 
17.03448 D3-Me-ester deuterated methyl ester 
17.026549 Ammonium replacement of proton with 
ammonium ion 
16.997557 Asn->Met Asn->Met substitution 
16.990164 Pro->Asn Pro->Asn substitution 
16.0313 Pro->Xle Pro->Leu/Ile substitution 
16.028204 DeMet Deuterium Methylation of Lysine 
16.027929 Met->Phe Met->Phe substitution 
16.013542 Asp->Met Asp->Met substitution 
15.994915 Hydroxylation Oxidation or Hydroxylation 
15.994915 Ala->Ser Ala->Ser substitution 
15.994915 Phe->Tyr Phe->Tyr substitution 
15.977156 thiocarboxy thiocarboxylic acid 
15.977156 Ser->Cys Ser->Cys substitution 
15.958529 Val->Asp Val->Asp substitution 
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15.958529 Xle->Glu Leu/Ile->Glu substitution 
15.010899 aminotyrosine Tyrosine oxidation to 2-aminotyrosine 
15.010899 Xle->Lys Leu/Ile->Lys substitution 
15.010899 Hydroxamic_acid ADP-ribosylation followed by 
conversion to hydroxamic acid via 
hydroxylamine 
14.999666 Methyl+Deamidated Deamidation followed by a 
methylation 
14.999666 Asn->Glu Asn->Glu substitution 
14.974514 Xle->Gln Leu/Ile->Gln substitution 
14.974514 Val->Asn Val->Asn substitution 
14.96328 aminoadipic alpha-amino adipic acid 
14.052036 Asn->Lys Asn->Lys substitution 
14.01565 Methyl Methylation 
14.01565 Asp->Glu Asp->Glu substitution 
14.01565 Gly->Ala Gly->Ala substitution 
14.01565 Ser->Thr Ser->Thr substitution 
14.01565 Val->Xle Val->Leu/Ile substitution 
14.01565 Asn->Gln Asn->Gln substitution 
13.979265 Pyroglutamic proline oxidation to pyroglutamic acid 
13.979265 oxolactone Tryptophan oxidation to oxolactone 
13.979265 Thr->Asp Thr->Asp substitution 
13.979265 Carbonyl aldehyde and ketone modifications 
13.06802 Asp->Lys Asp->Lys substitution 
13.031634 MethylamineST Michael addition with methylamine 
13.031634 Asp->Gln Asp->Gln substitution 
12.995249 Thr->Asn Thr->Asn substitution 
12.995249 Nitrene Loss of O2; nitro photochemical 
decomposition 
12.962234 Phe->CamCys Phe->Cys substitution and 
carbamidomethylation 
12.036386 Thr->Xle Thr->Leu/Ile substitution 
12.036386 Ser->Val Ser->Val substitution 
12.017759 Cys->Asp Cys->Asp substitution 
12 Thiazolidine formaldehyde adduct 
11.070128 Cys->ethylaminoAla Carbamidomethylated Cys that 
undergoes beta-elimination and 
Michael addition of ethylamine 
11.033743 Cys->Asn Cys->Asn substitution 
10.07488 Cys->Xle Cys->Leu/Ile substitution 
10.020735 Ser->Pro Ser->Pro substitution 
10.009502 His->Phe His->Phe substitution 
9.032697 Phe->Arg Phe->Arg substitution 
9.000334 Gln->His Gln->His substitution 
8.963949 Lys->His Lys->His substitution 
8.016319 Glu->His Glu->His substitution 
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6.962218 Arg->Tyr Arg->Tyr substitution 
6.018427 Met->His Met->His substitution 
6.008178 Cation:Li Replacement of proton by lithium 
5.956421 Pro->Cys Pro->Cys substitution 
4.97893 Formylasparagine In Bachi as Formylaspargine (typo?) 
3.994915 kynurenin tryptophan oxidation to kynurenin 
3.994915 Pro->Thr Pro->Thr substitution 
3.940771 Val->Cys Val->Cys substitution 
2.981907 Gln->Met Gln->Met substitution 
2.945522 Lys->Met Lys->Met substitution 
2.01565 Pro->Val Pro->Val substitution 
1.997892 Glu->Met Glu->Met substitution 
1.979265 Val->Thr Val->Thr substitution 
1.961506 Thr->Cys Thr->Cys substitution 
1.942879 Xle->Asp Leu/Ile->Asp substitution 
0.984016 Deamidation Deamidation 
0.984016 Asn->Asp Asn->Asp substitution 
0.984016 Gln->Glu Gln->Glu substitution 
0.958863 Xle->Asn Leu/Ile->Asn substitution 
0.94763 Lys->Glu Lys->Glu substitution 
0.036386 Gln->Lys Gln->Lys substitution 
-0.036386 Lys->Gln Lys->Gln substitution 
-0.94763 Glu->Lys Glu->Lys substitution 
-0.958863 Asn->Xle Asn->Leu/Ile substitution 
-0.984016 Amide Amidation 
-0.984016 Asp->Asn Asp->Asn substitution 
-0.984016 Glu->Gln Glu->Gln substitution 
-1.007825 Cystine Half of a disulfide bridge 
-1.031634 Lysaminoadipicsealde Lysine oxidation to aminoadipic 
semialdehyde 
-1.942879 Asp->Xle Asp->Leu/Ile substitution 
-1.961506 Cys->Thr Cys->Thr substitution 
-1.979265 Thr->Val Thr->Val substitution 
-1.997892 Met->Glu Met->Glu substitution 
-2.01565 didehydro 2-amino-3-oxo-butanoic_acid 
-2.01565 Val->Pro Val->Pro substitution 
-2.945522 Met->Lys Met->Lys substitution 
-2.945522 Cys->methylaminoAla carbamidomethylated Cys that 
undergoes beta-elimination and 
Michael addition of methylamine 
-2.981907 Met->Gln Met->Gln substitution 
-3.940771 Cys->Val Cys->Val substitution 
-3.994915 Thr->Pro Thr->Pro substitution 
-3.994915 Glu->pyro-Glu+Methyl Pyro-Glu from E + Methylation 
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-4.986324 Met->Aha Methionine replacement by azido 
homoalanine 
-5.956421 Cys->Pro Cys->Pro substitution 
-6.018427 His->Met His->Met substitution 
-6.962218 Tyr->Arg Tyr->Arg substitution 
-8.016319 His->Glu His->Glu substitution 
-8.963949 His->Lys His->Lys substitution 
-9.000334 His->Gln His->Gln substitution 
-9.032697 Arg->Phe Arg->Phe substitution 
-10.009502 Phe->His Phe->His substitution 
-10.020735 Pro->Ser Pro->Ser substitution 
-10.031969 Aspartylurea Aspartylurea 
-10.07488 Xle->Cys Leu/Ile->Cys substitution 
-11.033743 Asn->Cys Asn->Cys substitution 
-12.017759 Asp->Cys Asp->Cys substitution 
-12.036386 Xle->Thr Leu/Ile->Thr substitution 
-12.036386 Val->Ser Val->Ser substitution 
-12.995249 Asn->Thr Asn->Thr substitution 
-13.031634 Gln->Asp Gln->Asp substitution 
-13.06802 Lys->Asp Lys->Asp substitution 
-13.979265 Asp->Thr Asp->Thr substitution 
-14.01565 Ala->Gly Ala->Gly substitution 
-14.01565 Glu->Asp Glu->Asp substitution 
-14.01565 Xle->Val Leu/Ile->Val substitution 
-14.01565 Thr->Ser Thr->Ser substitution 
-14.01565 Gln->Asn Gln->Asn substitution 
-14.052036 Lys->Asn Lys->Asn substitution 
-14.974514 Gln->Xle Gln->Leu/Ile substitution 
-14.974514 Asn->Val Asn->Val substitution 
-14.999666 Glu->Asn Glu->Asn substitution 
-15.010899 lactic lactic acid from N-term Ser 
-15.010899 Lys->Xle Lys->Leu/Ile substitution 
-15.010899 ISD_z+2_ion ISD (z+2)-series 
-15.958529 Asp->Val Asp->Val substitution 
-15.958529 Glu->Xle Glu->Leu/Ile substitution 
-15.977156 Cys->Ser Cys->Ser substitution 
-15.994915 semialdehyde reduction 
-15.994915 Ser->Ala Ser->Ala substitution 
-15.994915 Tyr->Phe Tyr->Phe substitution 
-16.013542 Met->Asp Met->Asp substitution 
-16.027929 Phe->Met Phe->Met substitution 
-16.0313 Xle->Pro Leu/Ile->Pro substitution 
-16.990164 Asn->Pro Asn->Pro substitution 
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-16.997557 Met->Asn Met->Asn substitution 
-17.026549 Pyro-glu Pyro-glu from Q 
-17.026549 N-oxobutanoic Loss of ammonia 
-17.956421 Met->Xle Met->Leu/Ile substitution 
-17.974179 Asp->Pro Asp->Pro substitution 
-17.992806 oxoalanine oxoalanine 
-18.010565 Phospho+PL Dehydration 
-18.010565 Pyro_glu Pyro-glu from E 
-18.025821 Phe->Glu Phe->Glu substitution 
-18.973451 Phe->Lys Phe->Lys substitution 
-19.009836 Phe->Gln Phe->Gln substitution 
-19.042199 Arg->His Arg->His substitution 
-20.026215 azole Formation of five membered aromatic 
heterocycle 
-21.987721 Met->Hpg methionine replacement by 
homopropargylglycine 
-22.031969 His2Asp His->Asp substitution 
-23.015984 His2Asn His->Asn substitution 
-23.015984 Trp->Tyr Trp->Tyr substitution 
-23.974848 His->Xle His->Leu/Ile substitution 
-25.049393 Gln->Cys Gln->Cys substitution 
-25.060626 Arg->Met Arg->Met substitution 
-25.085779 Lys->Cys Lys->Cys substitution 
-26.004417 Tyr->His Tyr->His substitution 
-26.01565 Pro->Ala Pro->Ala substitution 
-26.033409 Glu->Cys Glu->Cys substitution 
-26.052036 Xle->Ser Leu/Ile->Ser substitution 
-27.010899 Asn->Ser Asn->Ser substitution 
-27.010899 Gln->Thr Gln->Thr substitution 
-27.047285 Lys->Thr Lys->Thr substitution 
-27.058518 Arg->Glu Arg->Glu substitution 
-27.994915 OxPro Pyrrolidone from Proline 
-27.994915 Asp->Ser Asp->Ser substitution 
-27.994915 Glu->Thr Glu->Thr substitution 
-28.006148 Arg->Lys Arg->Lys substitution 
-28.0313 Val->Ala Val->Ala substitution 
-28.0313 Met->Cys Met->Cys substitution 
-28.042534 Arg->Gln Arg->Gln substitution 
-28.990164 Gln->Val Gln->Val substitution 
-29.026549 Lys->Val Lys->Val substitution 
-29.974179 Glu->Val Glu->Val substitution 
-29.978202 Trp->Arg Trp->Arg substitution 
-29.992806 HSe Homoserine 
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-29.992806 Met->Thr Met->Thr substitution 
-30.010565 Pyrrolidinone Proline oxidation to pyrrolidinone 
-30.010565 Ser->Gly Ser->Gly substitution 
-30.010565 Thr->Ala Thr->Ala substitution 
-30.010565 Decarboxylation Decarboxylation 
-31.005814 Gln->Pro Gln->Pro substitution 
-31.042199 Lys->Pro Lys->Pro substitution 
-31.972071 Met->Val Met->Val substitution 
-31.972071 Cys->Ala Cys->Ala substitution 
-31.989829 Glu->Pro Glu->Pro substitution 
-32.008456 Met->AspSA Methionine oxidation to aspartic 
semialdehyde 
-32.022844 Tyr->Met Tyr->Met substitution 
-32.041471 Phe->Asp Phe->Asp substitution 
-33.003705 pyruvicC pyruvic acid from N-term cys 
-33.025486 Phe->Asn Phe->Asn substitution 
-33.98435 Phe->Xle Phe->Leu/Ile substitution 
-33.987721 DehydroalaC Dehydroalanine (from Cysteine) 
-33.987721 Met->Pro Met->Pro substitution 
-34.020735 Tyr->Glu Tyr->Glu substitution 
-34.049727 His->Cys His->Cys substitution 
-34.968366 Tyr->Lys Tyr->Lys substitution 
-35.004751 Tyr->Gln Tyr->Gln substitution 
-36.011233 His->Thr His->Thr substitution 
-37.990498 His->Val His->Val substitution 
-39.010899 Trp->Phe Trp->Phe substitution 
-40.006148 His->Pro His->Pro substitution 
-40.0313 Pro->Gly Pro->Gly substitution 
-41.026549 Gln->Ser Gln->Ser substitution 
-41.062935 Lys->Ser Lys->Ser substitution 
-41.074168 Arg->Asp Arg->Asp substitution 
-42.010565 Glu->Ser Glu->Ser substitution 
-42.021798 Arg2Orn Ornithine from Arginine 
-42.04695 Xle->Ala Leu/Ile->Ala substitution 
-42.04695 Val->Gly Val->Gly substitution 
-42.058184 Arg->Asn Arg->Asn substitution 
-43.005814 Asn->Ala Asn->Ala substitution 
-43.017047 Arg->Xle Arg->Leu/Ile substitution 
-43.053433 Argglutamicsealde Arginine oxidation to glutamic 
semialdehyde 
-43.989829 Asp->Ala Asp->Ala substitution 
-44.008456 Met->Ser Met->Ser substitution 
-44.026215 Thr->Gly Thr->Gly substitution 
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-44.059229 Phe->Cys Phe->Cys substitution 
-45.987721 Cys->Gly Cys->Gly substitution 
-46.005479 a-type_Ion ISD a-series (C-Term) 
-46.020735 Phe->Thr Phe->Thr substitution 
-48 Phe->Val Phe->Val substitution 
-48.003371 Hse_lact Homoserine lactone 
-48.003371 Dethiomethyl Prompt loss of side chain from oxidised 
Met 
-48.036386 Tyr->Asp Tyr->Asp substitution 
-49.020401 Tyr->Asn Tyr->Asn substitution 
-49.020401 Trp->His Trp->His substitution 
-49.979265 Tyr->Xle Tyr->Leu/Ile substitution 
-50.01565 Phe->Pro Phe->Pro substitution 
-50.026883 His->Ser His->Ser substitution 
-53.091927 Arg->Cys Arg->Cys substitution 
-55.038828 Trp->Met Trp->Met substitution 
-55.053433 Arg->Thr Arg->Thr substitution 
-56.0626 Xle->Gly Leu/Ile->Gly substitution 
-57.021464 Asn->Gly Asn->Gly substitution 
-57.021464 Gln->Ala Gln->Ala substitution 
-57.032697 Arg->Val Arg->Val substitution 
-57.03672 Trp->Glu Trp->Glu substitution 
-57.057849 Lys->Ala Lys->Ala substitution 
-57.98435 Trp->Lys Trp->Lys substitution 
-58.005479 Asp->Gly Asp->Gly substitution 
-58.005479 Glu->Ala Glu->Ala substitution 
-58.005479 Gly-loss+Amide Enzymatic glycine removal leaving an 
amidated C-terminus 
-58.020735 Trp->Gln Trp->Gln substitution 
-59.048347 Arg->Pro Arg->Pro substitution 
-60.003371 Met->Ala Met->Ala substitution 
-60.036386 Phe->Ser Phe->Ser substitution 
-60.054144 Tyr->Cys Tyr->Cys substitution 
-62.01565 Tyr->Thr Tyr->Thr substitution 
-63.994915 Tyr->Val Tyr->Val substitution 
-66.010565 Tyr->Pro Tyr->Pro substitution 
-66.021798 His->Ala His->Ala substitution 
-69.069083 Arg->Ser Arg->Ser substitution 
-71.037114 Gln->Gly Gln->Gly substitution 
-71.05237 Trp->Asp Trp->Asp substitution 
-71.073499 Lys->Gly Lys->Gly substitution 
-72.021129 Glu->Gly Glu->Gly substitution 
-72.036386 Trp->Asn Trp->Asn substitution 
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-72.995249 Trp->Xle Trp->Leu/Ile substitution 
-74.019021 Met->Gly Met->Gly substitution 
-76.0313 Tyr->Ser Tyr->Ser substitution 
-76.0313 Phe->Ala Phe->Ala substitution 
-80.037448 His->Gly His->Gly substitution 
-83.070128 Trp->Cys Trp->Cys substitution 
-85.031634 Trp->Thr Trp->Thr substitution 
-85.063997 Arg->Ala Arg->Ala substitution 
-87.010899 Trp->Val Trp->Val substitution 
-89.026549 Trp->Pro Trp->Pro substitution 
-89.02992 Met-loss+Acetyl Removal of initiator methionine from 
protein N-terminus, then acetylation of 
the new N-terminus 
-90.04695 Phe->Gly Phe->Gly substitution 
-92.026215 Tyr->Ala Tyr->Ala substitution 
-94.041865 DehydroalaY Dehydroalanine (from Tyrosine) 
-99.047285 Trp->Ser Trp->Ser substitution 
-99.079647 Arg->Gly Arg->Gly substitution 
-106.041865 Tyr->Gly Tyr->Gly substitution 
-115.042199 Trp->Ala Trp->Ala substitution 
-129.057849 Trp->Gly Trp->Gly substitution 
-131.040485 Met-loss Removal of initiator methionine from 
protein N-terminus 






Supplementary List 5. User file for Sticker. 
d Lab_User_label Cond_a 
  NoLab   
-458.325864 TMT-derived(-TMT(2)) N-term,K 
-442.330949 TMT-derived(-TMT(2)+O) N-term,K 
-422.325864 K-1-amino-3-iminopropene-K crosslink+2TMT-loss K 
-421.341848 K-1-amino-3-iminopropene-K crosslink+2TMT-loss+DEA K 
-406.330949 K-1-amino-3-iminopropene-K crosslink+2TMT-loss+OX K 
-404.315299 N-propenal+2-TMT-loss K 
-403.331283 N-propenal+2-TMT-loss+DEA K 
-388.320384 N-propenal+2-TMT-loss+OX K 
-376.312384 TMT-derived N-term,K 
-360.330488 TMT-derived C or Q on N-term, K 
-359.333453 TMT-derived C or Q on N-term, K 
-350.304734 2N-propenal +2TMT-loss K 
-344.276762 TMT-derived N-term,K 
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-320.172118 Cys-> Dha -TMT C 
-246.189481 TMT-derived C or Q on N-term 
-230.194566 TMT-derived C or Q on N-term 
-229.162932 TMT-derived N-term,K 
-228.282014 TMT-derived N-term,K 
-217.162932 TMT-derived ('-TMT+C) N-term 
-214.199652 Lys->AminoadipicAcid K 
-213.168017 TMT-derived (O-TMT) N-term 
-203.18058 TMT-derived N-term,K 
-201.168017 Formyl K 
-201.168017 TMT-derived (formyl-TMT) N-term 
-197.173102 TMT-derived (O(2)-TMT) N-term,K 
-187.185665 TMT-derived N-term,K,M 
-187.152367 Acetyl K 
-186.154031 TMT-derived N-term,K 
-175.152367 N-propenal+1TMT-loss K 
-174.168351 N-propenal+1TMT-loss+DEA K 
-172.138381 TMT-derived N-term,K 
-170.159116 TMT-derived N-term,K,M 
-159.157452 N-propenal+1TMT-loss+OX K 
-157.133802 TMT-derived N-term,K 
-156.143466 TMT-derived N-term,K,M 
-147.149452 TMT-derived N-term,K 
-143.162537 N-propenal+1TMT-loss+2OX K 
-143.126153 2-hydroxyisobutyrylation K 
-141.138887 TMT-derived N-term M 
-129.138887 TMT-derived N-term,K 
-121.141803 HydroxymethylOP K 
-115.120005 GG K 
-114.141007 TMT-derived N-term,K 
-113.143972 TMT-derived N-term,K 
-112.138097 HCysThiolactone K 
-103.009185 Cys->Gly-IAM C 
-98.146092 TMT-derived N-term,K 
-97.14905703 TMT-derived N-term,K 
-95.14234703 TMT-derived N-term 
-94.13899203 TMT-derived N-term 
-91.009186 Cys-> Dha  C 
-90.025169 Cys->PyruvicAcid-IAM C 
-88.993535 Cys->Ala-IAM C 
-82.151177 TMT-derived N-term,K 
-75.014270 Cys->Oxoalanine-IAM C 
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-72.998620 Cys->Ser-IAM C 
-72.11742303 TMT-derived N-term,K 
-67.110108 Hex K 
-62.977885 Cys->Pro-IAM C 
-60.962235 Cys->Val-IAM C 
-59.037114 S-S->Thioaldehyde C 
-58.982970 Cys->Thr-IAM C 
-56.12250803 TMT-derived N-term,K 
-46.946584 Cys->Xle-IAM C 
-45.987721 Cys->Asn-IAM C 
-45.003705 C->D-IAM C 
-33.987721 C_reduced (loss of oxidized, alkylated cysteine) C 
-31.972071 Cys->Gln-IAM C 
-31.935685 Cys->Lys-IAM C 
-30.988055 Cys->Glu-IAM C 
-28.990164 Cys->Met-IAM C 
-25.031634 C_sulfinic C 
-22.971737 Cys->His-IAM C 
-22.067486 2DTT-sensitive C ox C 
-12.995249 Cys->MetOx-IAM C 
-12.962235 Cys->Phe-IAM C 
-11.033743 DTT-sensitive C ox C 
-9.036719 C_sulfonic C 
-3.929537 Cys->Arg-IAM C 
-2.015650 S-S->Thioaldehyde; water-loss +ox C 
-1.031634 ammonia-loss+ox NA 
-1.012295 water-loss +ox+C13 NA 
-0.028279 ammonia-loss+ox+C13 NA 
3.032680 Cys->Tyr-IAM C 
4.978931 KYN+DEA W 
26.048664 Cys->Trp-IAM C 
36.000000 K-1-amino-3-iminopropene-K crosslink K 
49.955943 Cl+O W,Y 
54.010565 N-propenal K 
57.024551 TMT-derived S,H,T,K,M 
61.982636 MMTS+O C 
71.032095 TMT-derived N-term,K 
72.02912997 TMT-derived S,H,W,Y,M 
73.016379 IAM+O C 
73.019466 TMT-derived M 
89.014381 TMT-derived M 
91.975442 MMTS(2) C 
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100.024045 TMT-derived S,T 
152.980587 C_disulfur (CarbamidomethylDTT)+DEA C 
154.065171 LRGG K 
168.080821 K_LRGG+methyl K 
182.096471 K_LRGG+dimethyl K 
197.227247 Cys->Glu+TMT-IAM C 
209.018035 DTT+IAM C 
230.146948 TMT-derived N-term,K 
244.173831 NH+TMT Y 
245.157847 TMT-derived N-term,K 
246.189481 TMT-derived N-term,K 
261.152762 TMT-derived N-term,K 
261.152762 TMT-derived N-term,K 
286.184396 TMT-derived N-term,K 
297.084987 (+)TMT+CL(2) Y 
297.084987 TMT-derived Y 
298.069003 (+)TMT+CL(2)+DEA Y 
458.325864 TMT-derived S,T 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
